Clinical Application of Electrocardiographic Imaging in Patients with Ischemic Cardiomyopathy, Early Repolarization Syndrome and Brugada Syndrome by Zhang, Junjie
Washington University in St. Louis
Washington University Open Scholarship
Engineering and Applied Science Theses &
Dissertations McKelvey School of Engineering
Winter 12-15-2015
Clinical Application of Electrocardiographic
Imaging in Patients with Ischemic Cardiomyopathy,
Early Repolarization Syndrome and Brugada
Syndrome
Junjie Zhang
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/eng_etds
Part of the Engineering Commons
This Dissertation is brought to you for free and open access by the McKelvey School of Engineering at Washington University Open Scholarship. It has
been accepted for inclusion in Engineering and Applied Science Theses & Dissertations by an authorized administrator of Washington University Open
Scholarship. For more information, please contact digital@wumail.wustl.edu.
Recommended Citation
Zhang, Junjie, "Clinical Application of Electrocardiographic Imaging in Patients with Ischemic Cardiomyopathy, Early Repolarization
Syndrome and Brugada Syndrome" (2015). Engineering and Applied Science Theses & Dissertations. 144.
https://openscholarship.wustl.edu/eng_etds/144
WASHINGTON UNIVERSITY IN ST. LOUIS 
School of Engineering and Applied Science 
Department of Biomedical Engineering 
 
Dissertation Examination Committee: 
Yoram Rudy, Chair 
 Jianmin Cui 
Richard B. Schuessler 
Timothy W. Smith  
Pamela K. Woodard 
 
 
Clinical Application of Electrocardiographic Imaging  
in Patients with Ischemic Cardiomyopathy,  
Early Repolarization Syndrome and Brugada Syndrome 
 
by 
Junjie Zhang 
 
 
A dissertation presented to the  
Graduate School of Arts & Sciences 
of Washington University in 
partial fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 
 
December 2015 
St. Louis, Missouri  
ii 
 
Table of Contents 
List of Figures ................................................................................................................................. v 
List of Tables ................................................................................................................................ vii 
Acknowledgments........................................................................................................................ viii 
Abstract .......................................................................................................................................... xi 
Chapter 1: Introduction ............................................................................................................... 1 
1.1 The ECGI Methodology ................................................................................................... 2 
1.2 Validation of ECGI in Animal Models and Human Studies ............................................ 3 
1.3 Dissertation Organization ................................................................................................. 4 
Chapter 2: Noninvasive High-Resolution Cardiac Mapping in Ischemic Cardiomyopathy 
Patients: the Electrophysiological Substrate in Relation to Ventricular Arrhythmias and 
Arrhythmic Risk.............................................................................................................................. 6 
2.1 Abstract ............................................................................................................................ 6 
2.2 Introduction ...................................................................................................................... 7 
2.3 Methods ............................................................................................................................ 9 
2.3.1 Patient Population ................................................................................................................. 9 
2.3.2 Noninvasive Mapping ........................................................................................................... 9 
2.3.3 Data Analysis ...................................................................................................................... 10 
2.3.4 Statistical analysis ............................................................................................................... 12 
2.4 Results ............................................................................................................................ 13 
2.4.1 Characteristics of Abnormal EP Substrate .......................................................................... 14 
2.4.2 Relationship between Ventricular Arrhythmias and EP Substrate ...................................... 19 
2.4.3 Comparison of EP Substrate Properties between VT Patients and Non-VT patients ......... 21 
2.5 Discussion ...................................................................................................................... 23 
2.5.1 Key Findings ....................................................................................................................... 23 
2.5.2 The EP Scar Substrate ......................................................................................................... 24 
2.5.3 Substrate Mapping and Ablation ......................................................................................... 25 
2.5.4 ECGI-recorded Scar EGMs and Far-field Deflections ....................................................... 25 
2.5.5 Scar-related Arrhythmias .................................................................................................... 26 
2.5.6 Risk Stratification for VT ................................................................................................... 27 
iii 
 
2.5.7 Limitations .......................................................................................................................... 28 
2.6 Conclusions .................................................................................................................... 29 
2.7 Supplemental Material ................................................................................................... 29 
2.7.1 Maps of EP Substrate and Activation Sequence for VT Patients ....................................... 29 
2.7.2 Maps of EP Substrate for Non-VT Patients ........................................................................ 47 
2.7.3 Video Files (available in the attached CD): ECGI Activation Movies ............................... 62 
Chapter 3: The Electrophysiological Substrate of Early Repolarization Syndrome: 
Noninvasive Mapping in Patients ................................................................................................. 63 
3.1 Abstract .......................................................................................................................... 63 
3.2 Introduction .................................................................................................................... 64 
3.3 Methods .......................................................................................................................... 65 
3.3.1 Patient Population ............................................................................................................... 65 
3.3.2 Noninvasive Mapping ......................................................................................................... 66 
3.3.3 Data Analysis ...................................................................................................................... 66 
3.3.4 Statistical Analysis: ............................................................................................................. 67 
3.4 Results: ........................................................................................................................... 69 
3.4.1 EGM Characterization and Localization ............................................................................. 69 
3.4.2 Epicardial Activation .......................................................................................................... 71 
3.4.3 Epicardial Repolarization .................................................................................................... 74 
3.4.4 Ventricular Arrhythmias ..................................................................................................... 75 
3.5 Discussion: ..................................................................................................................... 77 
3.6 Conclusions: ................................................................................................................... 83 
Chapter 4: The Cardiac Electrophysiologic Substrate Underlying the ECG Phenotype and 
Electrogram Abnormalities in Brugada Syndrome Patients ......................................................... 84 
4.1 Abstract .......................................................................................................................... 84 
4.2 Introduction .................................................................................................................... 85 
4.3 Methods .......................................................................................................................... 87 
4.3.1 Patient Population ............................................................................................................... 87 
4.3.2 Noninvasive Mapping ......................................................................................................... 87 
4.3.3 Simulation ........................................................................................................................... 91 
4.3.4 Statistical Analysis .............................................................................................................. 91 
iv 
 
4.4 Results ............................................................................................................................ 92 
4.4.1 BrS Abnormal EGM Characteristics and Localization ....................................................... 92 
4.4.2 BrS Activation .................................................................................................................... 94 
4.4.3 BrS Repolarization .............................................................................................................. 96 
4.4.4 Effects of Increased HR in BrS ........................................................................................... 96 
4.4.5 Comparison between BrS and Non-BrS RBBB .................................................................. 98 
4.5 Discussion .................................................................................................................... 100 
4.5.1 Abnormal EGM Characteristics and Localization ............................................................ 101 
4.5.2 Substrate for Abnormal Conduction ................................................................................. 101 
4.5.3 Substrate for Abnormal Repolarization ............................................................................ 104 
4.5.4 Examining the Coexistence of Conduction and Repolarization Substrates Using 
Increased HR ..................................................................................................................... 106 
4.5.5 Comparison to Non-BrS RBBB ........................................................................................ 107 
4.5.6 Limitations ........................................................................................................................ 107 
4.6 Conclusions .................................................................................................................. 108 
Chapter 5: Concluding Remarks and Future Work ................................................................ 110 
5.1 Concluding Remarks .................................................................................................... 110 
5.2 Future Work ................................................................................................................. 111 
References ................................................................................................................................... 113 
Appendix:  Case Reports ............................................................................................................ 125 
A1. Continuous ECGI Mapping of Spontaneous VT Initiation, Continuation and 
Termination with Antitachycardia Pacing ............................................................................... 125 
A2. Electrophysiologic Mechanism of Deteriorating Cardiac Function in a Patient with 
Inappropriate CRT Indication and Frequent Ventricular Ectopy ............................................ 127 
Curriculum Vitae ........................................................................................................................ 130 
 
  
v 
 
List of Figures 
Figure 1-1:  ECGI Procedure ............................................................................................................ 3 
Figure 2-1:  Far-field Potential Identification. ................................................................................ 11 
Figure 2-2:  Representative Electrograms (EGMs) ......................................................................... 14 
Figure 2-3: The abnormal electrophysiological substrate in a non-VT patient (control) with an 
inferior infarct. ............................................................................................................. 16 
Figure 2-4:  The abnormal electrophysiological substrate in a VT patient (case) .......................... 17 
Figure 2-5:  The electrophysiological substrate in relation to ventricular arrhythmias. ................. 18 
Figure 2-6:  Comparison of the electrophysiological substrate properties between VT patients 
(case) and non-VT patients (control) ........................................................................... 21 
Figure 2-7:  Patient #1: VT patient; inferior myocardial infarction ................................................ 30 
Figure 2-8:  Patient #2: VT patient; inferior myocardial infarction ................................................ 31 
Figure 2-9:  Patient #3: VT patient; apical myocardial infarction .................................................. 32 
Figure 2-10: Patient #4: VT patient; apical myocardial infarction ................................................. 33 
Figure 2-11: Patient #5: VT patient; apical myocardial infarction ................................................. 34 
Figure 2-12: Patient #6: VT patient; inferior myocardial infarction............................................... 35 
Figure 2-13: Patient #7: VT patient; inferior and infero-lateral myocardial infarction .................. 36 
Figure 2-14: Patient #8: VT patient; anterior myocardial infarction .............................................. 37 
Figure 2-15: Patient #9: VT patient; inferior and infero-lateral myocardial infarction .................. 38 
Figure 2-16: Patient #10: VT patient; inferior and apical myocardial infarction ........................... 39 
Figure 2-17: Patient #11: VT patient; anterior and apical myocardial infarction ........................... 40 
Figure 2-18: Patient #12: VT patient; anterior and apical myocardial infarction ........................... 41 
Figure 2-19: Patient #13: VT patient; anterior, lateral and inferior myocardial infarction ............ 42 
Figure 2-20: Patient #14: VT patient; anterior myocardial infarction ............................................ 43 
Figure 2-21: Patient #15: VT patient; lateral, inferior and apical myocardial infarction ............... 44 
Figure 2-22: Patient #16: VT patient; anterior and apical myocardial infarction ........................... 45 
Figure 2-23: Patient #17: VT patient; inferior and apical myocardial infarction ........................... 46 
Figure 2-24: Patient #18: Non-VT patient; inferior myocardial infarction .................................... 47 
Figure 2-25: Patient #19: Non-VT patient; apical, inferior and infero-lateral myocardial 
infarction ..................................................................................................................... 48 
Figure 2-26: Patient #20: Non-VT patient; apical and inferior myocardial infarction ................... 49 
Figure 2-27: Patient #21: Non-VT patient; inferior myocardial infarction .................................... 50 
Figure 2-28: Patient #22: Non-VT patient; inferior myocardial infarction .................................... 51 
Figure 2-29: Patient #23: Non-VT patient; apical and inferior myocardial infarction ................... 52 
Figure 2-30: Patient #24: Non-VT patient; apical and inferior myocardial infarction ................... 53 
Figure 2-31: Patient #25: Non-VT patient; apical myocardial infarction ....................................... 54 
Figure 2-32: Patient #26: Non-VT patient; inferior myocardial infarction .................................... 55 
vi 
 
Figure 2-33: Patient #27: Non-VT patient; inferior myocardial infarction .................................... 56 
Figure 2-34: Patient #28: Non-VT patient; apical myocardial infarction ....................................... 57 
Figure 2-35: Patient #29: Non-VT patient; inferior myocardial infarction .................................... 58 
Figure 2-36: Patient #30: Non-VT patient; anterior, apical and inferior myocardial infarction ..... 59 
Figure 2-37: Patient #31: Non-VT patient; anterior and apical myocardial infarction ................... 60 
Figure 2-38: Patient #32: Non-VT patient; anterior and apical myocardial infarction ................... 61 
Figure 3-1:  Epicardial J-wave Distribution and Magnitude ........................................................... 70 
Figure 3-2:  Activation Isochrone Maps ......................................................................................... 71 
Figure 3-3:  Recovery Time (RT) Maps .......................................................................................... 72 
Figure 3-4:  Activation-recovery Interval (ARI) Maps ................................................................... 73 
Figure 3-5: The electrophysiological substrate in relation to premature ventricular contractions 
(PVCs) ......................................................................................................................... 76 
Figure 4-1:  ECGI Procedure and Parameters ................................................................................. 89 
Figure 4-2:  Abnormal Epicardial Electrograms (EGMs) Characteristics and Localization .......... 93 
Figure 4-3:  Activation and Repolarization during Sinus Rhythm .................................................. 94 
Figure 4-4: Effects of Increased Heart Rate (HR) .......................................................................... 97 
Figure 4-5:  Comparison between BrS and Non-BrS RBBB. ....................................................... 100 
Figure 4-6:  Computer Simulation of BrS Effects on a Human RVOT Action Potential ............. 105 
Figure A-1: Continuous ECGI Mapping of Spontaneous VT Initiation, Continuation and 
Termination with Antitachycardia Pacing ................................................................. 125 
Figure A-2: Activation Isochrone Maps during Native Sinus Rhythm and BiV Pacing .............. 128 
Figure A-3: PVC Activation Isochrone Maps with and without Pacing ...................................... 129 
 
 
 
  
vii 
 
List of Tables 
Table 2-1: Cumulative Patient Characteristics ............................................................................... 13 
Table 2-2: Comparison between VT Patients and Non-VT Patients .............................................. 23 
Table 3-1: Clinical Characteristics of the ERS Patients ................................................................. 69 
Table 3-2: Comparison of ECGI Parameters between ERS Patients and Normal Subjects ........... 75 
Table 4-1: BrS Patient Demographics ............................................................................................ 88 
Table 4-2: Cumulative Subject Characteristics............................................................................... 89 
Table 4-3: EGM Properties for BrS Patients .................................................................................. 92 
Table 4-4: Activation and Repolarization Parameters for BrS Patients ......................................... 95 
Table 4-5: Effects of Increased Heart Rate (HR) in BrS Patients ................................................... 98 
Table 4-6: A Comparison of ECGI Parameters between BrS and Non-BrS RBBB Patients ......... 99 
 
  
viii 
 
Acknowledgments 
This dissertation would not have been possible without the generous help from many people. 
First and foremost, I would like to express my sincere gratitude to my advisor Dr. Yoram Rudy for 
his extraordinary guidance and ceaseless support. Over the past few years, Dr. Rudy has helped me 
grow as a scientist and as a person. 
I would like to thank the dissertation committee members Dr. Jianmin Cui, Dr. Richard B. 
Schuessler, Dr. Timothy W. Smith, Dr. Pamela K. Woodard and former committee member Dr. 
Igor Efimov, for sharing their knowledge and providing valuable comments.  
This work benefited from the ideas and suggestions from our clinical collaborators. Barnes-
Jewish Hospital: Dr. Daniel H. Cooper, Dr. Phillip S. Cuculich, Dr. Mitchell N. Faddis, Dr. Jennifer 
Silva and Dr. Pamela K. Woodard; UCSF: Dr. Kurt Hoffmayer and Dr. Melvin Scheinman; 
Bordeaux University Hospital: Dr. Michel Haïssaguerre, Dr. Mélèze Hocini and Dr. Frédéric 
Sacher.  
I had the opportunity to work with and learn from a team of bright young scientists in the 
Rudy Laboratory. Thanks to them, my time in the lab was enjoyable and gratifying. ECGI group: 
Ramya Vijayakumar, Christopher Andrews, Dr. Subham Ghosh, Dr. Yong Wang and Dr. Kavit 
Desouza; Modeling group: Smiruthi Ramasubramanian, Jiajing Xu, Dr. Ashwin Mohan, Dr. Jordi 
Heijman, Dr. Pan Li, Dr. Namit Gaur, Dr. Tom O'Hara, Dr. Keith Decker, Dr. Ali Nekouzadeh and 
Dr. Leonid Livshitz. I would also like to thank our lab administrators Maya Bera, Huyen Nguyen, 
Kimberly Smith and Li Li for providing excellent assistance.  
 
ix 
 
Funding Sources: 
This work was supported by NIH–National Heart, Lung, and Blood Institute grants R01-
HL-033343 and R01-HL-049054 (to Dr. Yoram Rudy) and by Washington University Institute of 
Clinical and Translational Sciences grant UL1-TR000448 from the National Center for Advancing 
Translational Sciences of the NIH.    
Junjie Zhang 
Washington University in St. Louis 
August 2015 
  
x 
 
 
 
 
 
 
 
 
 
To my family  
 
for their relentless support 
  
xi 
 
ABSTRACT OF THE DISSERTATION 
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Washington University in St. Louis, 2015 
Professor Yoram Rudy, Chair 
 
 
Electrocardiographic Imaging (ECGI) is a noninvasive modality for human application in 
both research and clinical settings. It is an important tool for investigation of abnormal 
electrophysiological (EP) substrates and arrhythmias in patients. Multi-channel body surface 
potential recordings and the patient-specific heart-torso geometry from ECG gated computed 
tomography are processed by ECGI algorithms to reconstruct epicardial potentials, electrograms 
and patterns of activation and repolarization. ECGI is able to continuously generate high-resolution, 
panoramic EP maps of the entire heart on a beat-by-beat basis, which cannot be achieved with 
invasive catheter mapping. 
ECGI was applied in ischemic cardiomyopathy patients to characterize the abnormal EP 
substrate associated with myocardial infarction. In patients who developed ventricular tachycardia 
during the study, the arrhythmia activation pattern and site of origin were correlated with the EP 
xii 
 
substrate to identify components of the reentry circuit. The study subjects included patients with 
and without a history of clinical ventricular arrhythmias. The properties of scar EP substrate were 
compared between the two groups to determine whether substantial differences exist. This 
differentiating capability of ECGI was examined as a potential tool for arrhythmic risk stratification 
in this population. 
In a separate clinical study, ECGI was applied in a group of patients with early 
repolarization syndrome, which has been recently shown to be associated with an increased risk of 
ventricular fibrillation. The ventricular activation and repolarization patterns during sinus rhythm 
were characterized and compared with data from normal controls. This study aimed to provide 
insights into the mechanisms of the early repolarization ECG pattern and the related 
arrhythmogenesis.  
ECGI was also applied in patients with Brugada syndrome to image the EP substrate and to 
study the underlying mechanisms of the Brugada ECG pattern and abnormal epicardial 
electrograms. Heart rate change protocol in selected patients helped unmask the coexistence of 
abnormal conduction and abnormal repolarization in the EP substrate. Brugada syndrome patients 
were also compared with patients with right bundle branch block (generally considered benign) to 
determine whether the substrate was specific to Brugada syndrome, and whether ECGI can 
differentiate between these two pathologies with similar ECG patterns.  
The above studies demonstrated the feasibility and clinical importance of ECGI for 
noninvasive diagnosis, pre-procedural guidance and arrhythmic risk stratification in human subjects.
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Chapter 1: Introduction 
Cardiac electrical activity is a complex process. Each cardiac cycle starts with fast 
depolarization of the myocytes in the sinoatrial node. The electrical impulse spreads to the 
myocardium via the cardiac conduction system. The ordered and rhythmic excitation of the 
myocardium during each cardiac cycle ensures efficient contraction of the heart. Immediately after 
the depolarization phase, the myocardial cells start to repolarize, a relatively slow process that 
brings the membrane potential back to the resting voltage. 
Pathological changes can affect the membrane excitability (by down-regulating the sodium 
current), change the tissue structure (by causing fibrosis or by affecting gap-junction expression 
and distribution), and modify myocardial refractoriness (by disturbing current balance during the 
repolarization phase). These electrophysiological (EP) and structural changes can lead to slow, 
discontinuous propagation of the action potential through the cardiac tissue and steep gradients of 
myocardial repolarization, creating abnormal EP substrates that support initiation and maintenance 
of fatal reentrant arrhythmias. 
The 12-lead ECG is the only routine noninvasive tool for diagnosis and detection of cardiac 
rhythm disorders. Since its first introduction in 1902 by Einthoven, the 12-lead ECG has become 
a major clinical tool in assessing the function of the heart. However, in clinical practice, it is 
difficult to relate the ECG signals directly to the actual electrical activation and recovery processes 
in the heart. Each ECG electrode on the body surface records a signal that reflects integrated 
electrical activity over the entire heart. The ECG recordings are also smoothed by the torso-volume 
conductor. Therefore, the conventional 12-lead ECG lacks spatial resolution, sensitivity and 
specificity.  
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Electrocardiographic Imaging (ECGI)1-20 is a noninvasive modality for human application 
in both research and clinical settings. It has become an important tool for investigation of 
arrhythmogenic substrates and arrhythmias in patients. ECGI overcomes the limitations of 
conventional ECG by providing physiologically relevant information about cardiac electrical 
activity and reconstructing the actual spatial properties on the surface of the heart.  
1.1 The ECGI Methodology  
The electric potential field ϕ, generated by excitation of the heart in the surrounding torso 
volume between the epicardium and the body surface, obeys Laplace’s equation. Torso surface 
potentials (ϕT) can be measured by electrodes placed on the body surface. ϕE, epicardial potentials, 
is the unknown variable to be solved for. Application of Green’s second theorem and discretization 
of the epicardial and torso surfaces into triangular elements yields the following matrix equation 
relating ϕT to ϕE:21 
A ϕE  = ϕT         1.1 
The transfer matrix A contains the heart-torso geometric information. The objective of ECGI is to 
compute ϕE from a known ϕT, a procedure that constitutes the inverse problem of 
electrocardiography. The inverse problem is ill-posed22-23 in the sense that direct inversion of 
transfer matrix A leads to unstable solution. Two different computational schemes have been 
applied to suppress errors in the inverse solution: Tikhonov regularization22-23 (a method that 
imposes constraints on ϕE) and the generalized minimal residual (GMRes) iterative technique.9, 24  
The ECGI procedure is shown in Figure1-1. To obtain ϕT, multi-electrode strips are applied 
to the patient’s torso; up to 256 electrocardiograms are recorded simultaneously. To obtain transfer 
matrix A, the patient-specific heart-torso geometry is acquired via ECG-gated computed 
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tomography. These two sets of data are processed by ECGI algorithms to reconstruct epicardial 
potentials, unipolar electrograms (EGMs), and high-resolution maps of activation and 
repolarization. The reconstruction is performed during a single beat and does not require 
accumulating data from multiple identical beats. This property makes it possible to image non-
sustained and polymorphic arrhythmias, and arrhythmias that are not hemodynamically tolerated. 
 
Figure 1-1: ECGI Procedure  
The noninvasive ECGI procedure. Body surface potential recordings (256 electrodes) and gated, 
non-contrast thoracic computed tomography scan are processed mathematically to obtain 
epicardial potentials, 1500 unipolar electrograms, and maps of epicardial activation and 
repolarization. 
  
1.2 Validation of ECGI in Animal Models and Human Studies 
Validation experiments in animal models showed that ECGI can reconstruct EGMs with 
good accuracy, including in infarcted hearts, where EGMs inside the scar region display low 
potentials and fractionation.1-2, 4-5 ECGI was also shown to accurately reconstruct repolarization 
properties and to localize areas of increased dispersion of repolarization.6 Later, ECGI was 
validated in human subjects with direct intra-operative mapping during open-heart surgery.11 It 
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was shown that ECGI-reconstructed isochrones captured sites of earliest activation, areas of slow 
conduction, and the general excitation pattern. In addition, ECGI demonstrated a high spatial 
resolution of 6 mm for determining initiation sites (induced by pacing).  
Recently, ECGI was applied to study patients with a history of myocardial infarction.16 The 
location, size and shape of the electrical scar imaged by ECGI co-localized to the anatomic scar 
imaged by late gadolinium enhancement MRI or single-photon emission computed tomography 
with high accuracy. In a separate study, diverse ventricular arrhythmia activation patterns, 
mechanisms, and sites of origin in human subjects have been described in detail using ECGI.17 
These studies in humans showed great promise and paved the way for further clinical application 
of this novel technique as presented in this dissertation.   
1.3 Dissertation Organization 
Chapter 2: Application of ECGI in ischemic cardiomyopathy (ICM) patients. Scar-
related ventricular arrhythmias are the most common cause of rhythm disorders and sudden cardiac 
death (SCD) in patients who suffered myocardial infarction. Catheter ablation utilizing activation 
mapping and substrate mapping has evolved to treat scar-related ventricular arrhythmias. However, 
this invasive mapping procedure is difficult, time consuming and involves substantial risk. Given 
the increased risk of SCD associated with scar-related arrhythmias, the implantable cardioverter-
defibrillator (ICD) has been prescribed for ICM patients. The clinical criterion for ICD 
implantation in these patients is based almost exclusively on reduced left ventricular ejection 
fraction. However, only a small percentage of ICM patients who undergo device implantation 
receive appropriate shocks, making the reactive therapy with ICD unsatisfactory. In this study, 
noninvasive ECGI is used to map the EP substrate and VT circuits with high resolution and to 
stratify arrhythmic risk in ICM patients.  
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Chapter 3: Application of ECGI in early repolarization syndrome (ERS) patients: 
The ER pattern is a common ECG finding. Recent studies established a definitive clinical 
association between ER and fatal ventricular arrhythmias. Although ER has been extensively 
studied at the molecular and cellular levels, information on the EP substrate and arrhythmic 
behaviors of the intact human heart in vivo, where arrhythmias occur, is missing. With limited 
sensitivity, specificity and spatial resolution, the ECG characteristics are inadequate measures of 
the underlying activation and repolarization properties. The aim of this study is to characterize the 
epicardial EP substrate in ERS patients and to investigate how ERS predisposes patients to an 
increased risk of ventricular arrhythmias.  
Chapter 4: Application of ECGI in Brugada syndrome (BrS) patients: BrS is a highly 
arrhythmogenic cardiac disorder, associated with an increased incidence of SCD. It is estimated 
that BrS causes approximately 20% of SCD in cardiac patients with structurally normal heart. 
Understanding its pathophysiological mechanisms is essential for improving risk stratification, 
diagnosis and treatment to prevent SCD. While much is known at the molecular and cellular scales, 
understanding the cause of the BrS ECG pattern and associated arrhythmias requires detailed 
characterization of the EP substrate in the intact hearts of BrS patients. The goal of this study is to 
characterize the EP substrate in BrS patients using high-resolution panoramic EP maps generated 
by ECGI, in an effort to provide insight into the mechanistic origin of the BrS phenotype. 
Chapter 5 finishes the dissertation with concluding remarks and a discussion of future 
work that can be done to improve the work presented here.  
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Chapter 2: Noninvasive High-Resolution Cardiac Mapping in 
Ischemic Cardiomyopathy Patients: the Electrophysiological 
Substrate in Relation to Ventricular Arrhythmias and Arrhythmic 
Risk 
2.1 Abstract 
Ventricular tachycardia (VT) occurs frequently in the setting of myocardial infarction. 
Additional methods are needed for mapping the electrophysiological (EP) substrate and VT 
circuits with high resolution and for stratifying VT risk in ischemic cardiomyopathy (ICM) 
patients. 
Noninvasive epicardial mapping with Electrocardiographic Imaging (ECGI) was 
performed in 32 patients with ICM (17 with clinical VT, 15 without VT). Abnormal EP scar 
substrate was determined based on low electrogram voltage (as percentage of maximal peak-to-
peak voltage over the entire ventricular epicardium; total scar-TS <30%; dense scar-DS <15%). 
Scar burden was defined as the ratio of the scar size to the total epicardial surface area. Scar 
heterogeneity was characterized by presence of electrogram fractionation. Late potentials (LPs) 
were deflections that occurred after completion of global epicardial activation. Patients with VT 
had higher scar burden (TS: 51.0±9.3% vs. 36.5±5.4%, p<0.05; DS: 29.5±7.3% vs. 16.8±6.8%, 
p<0.05) with lower unipolar electrogram voltage (TS: 1.34±0.34 vs. 1.91±0.39 mV, p<0.05; DS: 
0.91±0.29 vs. 1.22±0.33 mV, p<0.05), greater prevalence of fractionated electrograms (TS: 
44.1±10.6% vs. 26.8±6.3%, p<0.05; DS: 50.8±10.8% vs. 30.9±7.0%, p<0.05) and LPs (TS: 
26.8±10.7% vs. 15.8±5.3, p<0.05). VTs were mapped in 8 patients; the reentry circuits were 
closely related to the EP substrate. 
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ECGI identifies scar EP properties that underlie abnormal conduction and VT in ICM 
patients. It also correlates VT activation patterns with the scar EP substrate. ECGI can potentially 
be used for VT risk stratification in ICM patients.  
2.2 Introduction 
Scar-related ventricular arrhythmias are the most common cause of rhythm disorders and 
sudden cardiac death (SCD) in patients who suffered myocardial infarction (MI). Healed infarcts 
can produce abnormal electrophysiological (EP) substrates that support arrhythmogenicity. With 
inexcitable scar tissue separating islands of surviving myocardial fibers, the EP substrate tends to 
have an inhomogeneous structure.25-26 This heterogeneity is associated with slow discontinuous 
conduction, direction-dependent conduction blocks and the presence of conducting channels 
within the scar, which can ultimately facilitate the formation and maintenance of reentrant 
arrhythmias.27-29  
Catheter ablation utilizing activation mapping (complemented by entrainment and pace-
mapping) has evolved to treat scar-related VT with up to 75% success rate after successful 
mapping procedures.30 However, non-sustained, non-inducible, or hemodynamically unstable VTs 
cannot be mapped by this technique. Alternatively, substrate mapping can be performed during 
sinus rhythm (SR), which does not require prolonged periods of ventricular tachycardia (VT). This 
procedure identifies the EP substrate associated with myocardial scars. In the scar, regions with 
low-voltage, fractionated electrograms (EGMs), slow conduction and late potentials (LPs) are 
considered critical components for reentrant arrhythmias.31-33 This information is used to guide 
substrate-based ablation for interruption of the reentry circuit and elimination of VT. However, the 
invasive mapping procedure is difficult, time consuming and involves substantial risk. Moreover, 
it only maps the substrate, instead of the actual reentry circuit. Due to the point-by-point sampling 
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nature of catheter mapping, some critical sites might be missed. Thus, a need exists to develop 
alternative techniques to map both the VT circuits and the EP substrate with high resolution.   
Given the increased risk of SCD associated with scar-related arrhythmias, the implantable 
cardioverter-defibrillator (ICD) has been prescribed for ischemic cardiomyopathy (ICM) patients. 
The clinical criterion for ICD implantation in these patients is based almost exclusively on reduced 
left ventricular ejection fraction (LVEF).  However, approximately 20% of ICM patients who 
undergo device implantation receive appropriate shocks, making the reactive therapy with ICD 
unsatisfactory.34 Clearly, new methods and better criteria are needed for arrhythmia risk 
stratification of ICM patients. 
Recent developments in noninvasive Electrocardiographic Imaging (ECGI; also called 
ECG mapping, ECM) have demonstrated its clinical usefulness in studying the EP properties and 
mechanisms of a variety of pathologies in the intact human heart. ECGI provides panoramic, high-
resolution EP data with up to 1,500 unipolar epicardial EGMs that cover both ventricles, from 
which epicardial maps of activation and repolarization can be generated.1, 5, 10, 13, 16-17, 20 Important 
to this study, ECGI can identify and characterize the abnormal EP substrate (low-voltage, 
fractionated EGMs and the presence of LPs) on the epicardial aspect of myocardial scars.5, 16 The 
location, size and shape of the electrical scar imaged by ECGI co-localized to the anatomic scar 
imaged by late gadolinium enhancement MRI (LGE-MRI) or single-photon emission computed 
tomography (SPECT) with high accuracy.16 In addition, ECGI mapping is accomplished during a 
single beat, making it capable of mapping premature ventricular contractions (PVCs), and 
polymorphic and unstable VTs. Diverse VT activation patterns, mechanisms, and sites of origin in 
human subjects have been described in detail using ECGI.17  In the current study, based on high-
resolution ECGI data recorded during sinus rhythm (SR), we characterize the EP substrate in ICM 
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patients. We correlate the activation pattern and site of origin during VT (if present) with the EP 
substrate map to identify components of the reentry circuit. We also compare the EP substrate 
between ICM patients with and without VT, to determine whether substantial differences in EP 
properties exist. This differentiating capability of ECGI is examined as a potential tool for 
arrhythmic risk stratification in ICM patients.  
2.3 Methods 
2.3.1 Patient Population 
The control group consisted of ICM patients with (1) history of MI (at least 6 months 
elapsed since the most recent MI), (2) systolic dysfunction with left ventricular ejection fraction 
(LVEF) ≤35%, (3) an implantable cardioverter-defibrillator (ICD) inserted based on primary 
prevention criteria, and (4) no history of clinical ventricular arrhythmias, syncope or cardiac arrest 
for at least 48 months since ICD insertion. The case group shared criteria (1) and (2) with the 
control group. In addition, the case group patients experienced at least one episode of clinical VT 
post-MI. These patients may have an ICD inserted for the primary prevention of SCD, but it was 
not required. Patients with the following conditions were excluded:35 (1) Surgical or percutaneous 
revascularization within the last 6 months; (2) Decompensated cardiac failure within the last 
month; (3) Uncontrolled hypertension; (4) Active cerebrovascular disease (or stroke within the last 
6 months); (5) Electrolyte abnormalities. All protocols were approved by the Institutional Review 
Boards at Washington University; written informed consent was obtained from all patients. 
2.3.2 Noninvasive Mapping 
ECGI methodology was described previously.1, 5, 10, 13, 16-17, 20 Multi-channel body surface 
potential mapping with 256 electrodes was performed during SR in all patients and during 
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arrhythmic period in patients who developed VT or PVCs at the time of the study. Patient-specific 
heart-torso geometry was obtained via non-contrast ECG-gated computed tomography. The heart-
torso geometrical information was combined with the body surface potential data to noninvasively 
reconstruct epicardial potentials, unipolar electrograms, and high-resolution maps of activation, 
repolarization and EP substrate associated with myocardial scar. The method was validated 
extensively for reconstruction of EGMs,1, 5 activation10, 13 and repolarization.13  
Clinical noninvasive cardiac imaging, including LGE-MRI (2 patients) and myocardial 
perfusion imaging with SPECT (30 patients), was available for comparing anatomical scar to 
ECGI-reconstructed electrical scar. 
2.3.3 Data Analysis 
Characteristics of the abnormal EP substrate associated with MI were analyzed by using 
data recorded during SR. EGM magnitude was measured peak-to-peak during the EGM QRS. 
Because the absolute EGM magnitude was influenced by patient-specific factors such as body 
habitus and heart-torso geometry, the EP substrate was defined based on EGM magnitude as a 
percentage of the maximal EGM magnitude of all EGMs reconstructed over the entire epicardium 
for each patient (total scar: <30%; dense scar: <15%; peripheral scar: between 15% and 30%). Scar 
burden was defined based on the size of total scar, dense scar and peripheral scar as a percentage 
of total epicardial surface area.  
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Figure 2-1: Far-field Potential Identification.  
Panel A shows a unipolar EGM reconstructed in the scar region. It is of low voltage and includes 
3 deflections (squares). The timing of the second deflection matches the activation time of a 
remote EGM (Panel B, about 2 cm away). Therefore, it was considered far-field potential and 
was excluded from fractionation analysis. 
 
The spatial resolution of ECGI was about 2 to 6 mm.12 The degree of scar heterogeneity 
was quantified by EGM fractionation. Fractionation was expressed as the number of intrinsic, 
sharp deflections (dV/dt <-0.05 V/s) per EGM. Each EGM reflected the electrical activity in 
cardiac tissue beneath and adjacent to the EGM location. For fractionated EGMs, deflections due 
to far-field activities were identified if the timing of the deflections matched the timing of 
deflection(s) in neighboring EGMs, remote EGMs, or both (Figure 2-1). Far-field deflections were 
marked and excluded for fractionation analysis. The remaining deflections were considered local 
activations. The sharpest local activation with the maximal negative slope was used to create the 
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global activation isochrone map.  LPs were defined as local activations with magnitude above the 
ambient electrical noise level that occurred after the completion of global epicardial activation.  
The presence of conducting channels within abnormal EP substrate was inferred if a 
continuous region of higher amplitude signals within the substrate could be observed after 
adjusting the threshold and color scale of the EGM voltage map. 
Activation time (AT) was determined by the maximal negative slope of the EGM during 
QRS inscription. All ATs were referenced to the beginning of QRS in ECG lead II. Epicardial 
activation isochrone maps were created from ATs. Lines of conduction block were inferred if 
adjacent ATs differed by more than 50 ms. Slow conduction was represented by crowded 
isochrones. 
Local recovery time (RT), which reflects the sum of local AT and local action potential 
duration (APD), was determined from the maximal positive slope of the EGM T-wave. For a given 
activation sequence, RT determines spatial voltage gradients during repolarization. Activation-
recovery interval (ARI) was defined as the difference between RT and AT. ARI is independent of 
AT and a surrogate for local APD.  
ECGI analyzed ventricular arrhythmias from a single beat and did not require accumulating 
data from multiple identical beats. Each arrhythmia was characterized and analyzed based on the 
global activation isochrones, properties of local EGMs, and patterns of wavefront propagation and 
its relationship to the EP substrate.   
2.3.4 Statistical analysis 
All continuous data are presented as mean± SD. Categorical data were analyzed by the chi-
square test (or Fisher’s exact test). Continuous variables were analyzed by unpaired t-test. The 
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Satterthwaite modified t-test was used for variables with unequal variances. The Mann-Whitney 
U test was used for variables with non-normal distribution. All tests with P<0.05 were considered 
statistically significant. Statistical analysis was performed by using SPSS v19.  
2.4 Results 
Between March 2010 and March 2014, 32 ICM patients were enrolled in this study, 
including 15 patients with no history of clinical ventricular arrhythmias (control group) and 17 
patients with spontaneous VT (case group). Patient characteristics are provided in Table 2-1. 
Overall, the two groups had similar characteristics in terms of age, gender, LVEF, QRS duration, 
Characteristics 
Case Group:  
VT Patients 
Control Group: 
Non-VT Patients 
P 
Value 
N 17 15  
Age, years 70±10 68±15 NS 
Male 16(94%) 13(87%) NS 
Left ventricular ejection 
fraction , % 
24±6 25±5 NS 
QRS duration, ms 135±22 142±25 NS 
Mean time since MI, 
months 
90±31 96±21 NS 
 
Infarct 
Location 
Anterior 6(35%) 3(20%) NS 
Inferior 9(53%) 11(73%) NS 
Apical 10(59%) 8(53%) NS 
Beta-blocker 17(100%) 15(100%) NS 
ACE/ARB 17(100%) 15(100%) NS 
Amiodarone 14 0 <0.001 
Other antiarrhythmic drugs 6 0 <0.001 
Table 2-1: Cumulative Patient Characteristics 
Data are presented as mean±SD or number (percentage). ACE= angiotensin-converting enzyme 
inhibitors; ARB= angiotensin receptor blockers; MI= myocardial infarction; NS= not significant; 
VT= ventricular tachycardia. 
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time since MI and infarct distribution. All patients were treated by beta-blocker and angiotensin-
converting enzyme inhibitors/ angiotensin receptor blockers. All case group patients were treated 
by antiarrhythmic drugs, whereas none of the control patients were on antiarrhythmic drugs.  
2.4.1 Characteristics of Abnormal EP Substrate 
Figure 2-2A shows a reconstructed epicardial unipolar EGM (top) and its time derivatives 
(dV/dt; bottom) from inside a scar. The time derivative approximates a bipolar EGM and helps to 
emphasize fractionation. In this example, the EGM has low voltage and 3 deflections, reflecting 3 
local activation events. The second deflection has the sharpest negative slope and was taken as the 
AT for constructing the global isochrone map. The third deflection occurred after the completion 
of global epicardial activation (the latest activation over both ventricles) and was considered a LP. 
 
Figure 2-2: Representative Electrograms (EGMs)  
Panel A: EGM from scar region. Panel B: EGM from non-scar region. Each panel shows a 
reconstructed unipolar EGM (top) and the corresponding time derivatives (dV/dt; bottom). The 
time derivative approximates a bipolar EGM and emphasizes fractionation. Squares indicate 
intrinsic sharp deflections (steep negative dV/dt), reflecting local activation. The dashed line 
indicates the time when global epicardial activation has been completed. L= local activation, G= 
global activation, LP= late potential. Note that the EGM from the scar region has a low voltage 
and multiple deflections. 
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A normal EGM at a site remote from the scar and its derivative are shown in Figure 2-2B for 
reference. 
Examples of abnormal EP substrate in a non-VT patient and a VT patient are shown in 
Figure 2-3 and Figure 2-4, respectively. Data for all patients are shown in the supplemental 
material (Section 2.7, Figure 2-7 to Figure 2-38). EP substrate for a non-VT patient is shown in 
Figure 2-3. Patient #27 was a 69 year-old male with LVEF of 28%. After suffering MI in 2006, he 
received a pacemaker/ICD device for primary prevention of SCD. He never had any arrhythmic 
event since the ICD insertion. Based on SPECT images (Panel F), large irreversible perfusion 
abnormality of marked severity involved the entire inferior, infero-lateral and infero-septal walls. 
The voltage map identified the electrical scar on the inferior wall (Panel B, red). By adjusting the 
threshold and color scale of the voltage map, the scar architecture could be observed and studied 
with high-resolution. The dense scar (Panel C, orange) separated strands of tissue with preserved 
voltage (Panel C, cyan).  Fractionated EGMs (Panel D, yellow, red) and late potentials (Panel E, 
red) were seen inside the electrical scar.  Normal human epicardial activation during SR was 
reported previously.13 In general, ventricular epicardial activation starts with right ventricular (RV) 
breakthrough, then propagates smoothly and uniformly towards the basal lateral left ventricle 
(LV).  Activation isochrone map in this patient (Panel A) showed that the epicardial activation 
pattern during SR was altered by the presence of the inferior scar. After the normal RV 
breakthrough (asterisk), the activation wavefront could not proceed towards the inferior RV (line-
of-block at the scar border, black arrows). This forced activation of the inferior wall in a left-to-
right pattern, leaving the inferior RV the latest region to activate. The scar burden in this patient 
was: total scar =30%, dense scar =14%, peripheral scar =16% of total epicardial surface area. 
Prevalence of fractionated EGM was 28% in the total scar, 32% in the dense scar and 25% in the 
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peripheral scar. Prevalence of LP was 10% in the total scar, 12% in the dense scar and 9% in the 
peripheral scar.   
 
Figure 2-3: The abnormal electrophysiological substrate in a non-VT patient (control) 
with an inferior infarct. 
Panel A: Activation isochrone map. Panel B Global voltage map; magnitude of unipolar 
electrograms. Panel C: High-resolution scar voltage map with adjusted threshold and color scale. 
Panel D: Electrogram fractionation; number of intrinsic deflections per electrogram. Panel E: 
Late potentials; regions with late potentials shown in red. Panels A-E display the heart in anterior 
view (left) and inferior view (right). Panel F: Single-photon emission computed tomography 
(SPECT) anatomic scar in a standard “bullseye” configuration or apical view (left) and long-axis 
view (right). In panel A, epicardial breakthrough is indicated by an asterisk, isochrones are 
depicted with thin black lines, and black arrows point to conduction block at the border of the 
inferior infarct. LA= left atrium; LV= left ventricle; RA= right atrium; RV= right ventricle. 
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Figure 2-4: The abnormal electrophysiological substrate in a VT patient (case)  
This patient had a large apical infarct, extending anteriorly and inferiorly. Same format as Figure 
2-3. In panel A, black arrows point to conduction block along the septum. 
 
 
Figure 2-4 shows the EP substrate in a VT patient. Patient #3 was a 72 year-old male with 
LVEF of 27%. He had multiple episodes of MI in 1980, 1987 and 1990, complicated by VTs.  
SPECT images (Panel F) suggested the presence of large, severe infarct involving the anterior, 
inferior, septal, and lateral walls and centering on the apex. ECGI co-localized an extensive apical 
scar that extended into the mid-myocardium (Panel B, red and orange). The only region with 
normal-voltage EGMs was the ventricular base. High-resolution voltage map identified several 
corridors with higher voltage (Panel C, light blue, green; near apex, inferior wall and lateral wall) 
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that penetrated the dense scar. Fractionated EGMs (Panel D, yellow, red) and late potentials (Panel 
E, red) were seen inside the electrical scar. Activation isochrone map (Panel A) showed a delayed 
activation of the LV as a result of the extensive infarct. Lines-of-block (black arrows) were seen 
over the interventricular septum. Anterior and inferior LV base were the latest regions to activate, 
about 80 ms later than in normal hearts.13 The scar burden in this patient was: total scar =67%, 
dense scar =44%, peripheral scar =23% of total epicardial surface area. Prevalence of fractionated 
EGM was 58% in the total scar, 59% in the dense scar and 56% in the peripheral scar. Prevalence 
of late potentials was 39% in the total scar, 31% in the dense scar and 43% in the peripheral scar.   
 
Figure 2-5: The electrophysiological substrate in relation to ventricular arrhythmias.  
Panel A: Apical scar related ventricular tachycardia (VT) with a single reentrant loop. Panel B: 
Anterior scar related VT with a double-loop pattern. Each panel shows the VT activation map 
(top), possible conducting channels (dashed lines) that facilitated VT (bottom left), a fractionated 
electrogram (EGM) with late potentials (LPs) during sinus rhythm (SR) (bottom right; yellow 
arrows point to EGM location). The VT initiation sites are indicated by plus signs “+”. In top 
panels, zigzag arrows indicate very slow conduction that crossed the scar border and reentered 
the VT initiation site. In panel A, the white arrows indicate a clockwise apical loop. In panel B, 
the white arrows indicate propagation of the inferior wavefront and the black arrows indicate 
propagation of the superior wavefront.  CL= cycle length. Activation movies for both VTs are 
provided in the attached CD (Movie 2-1 and Movie 2-2, respectively).   
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2.4.2 Relationship between Ventricular Arrhythmias and EP Substrate 
Figure 2-5 presents two examples of scar-related reentrant VT. Panel A shows an apical 
scar related VT with a simple activation pattern from patient #3 (substrate shown in Figure 2-4). 
A short run of non-sustained VT with a cycle length (CL) of 410 ms was recorded and analyzed. 
The earliest epicardial activation was in the anterior mid wall near the septum (plus sign), a 
peripheral scar region based on the EGM voltage criterion. The activation wavefront exited the 
anterior wall at the beginning of the VT beat, then activated sequentially in a clockwise pattern the 
lateral LV, inferior wall and anterior RV (white arrows),  and reentered to complete one VT cycle 
(zigzag arrow). A movie of the activation sequence is provided in the attached CD (Movie 2-1).  
Panel B presents an anterior scar related VT with a complex activation pattern from patient #8 
(substrate shown in Figure 2-14, Page 37). The patient developed non-sustained VT (CL =397 ms) 
during the ECGI procedure. The site of VT origin was located in the anterior mid wall near the 
apex, inside a region of the scar with preserved voltage (plus sign). The activation wavefront exited 
this region in two directions. The inferior wavefront propagated towards the apex (white arrows) 
then towards the inferior wall before it entered the anterior mid-RV, forming a clockwise apical 
loop.  The superior wavefront propagated towards the base then bifurcated (black arrows). The left 
branch of the superior wavefront activated the LV base, and merged with the inferior wavefront at 
the inferior base. The right branch of the superior wavefront circumvented the dense scar, then 
propagated slowly into the superior RV in a counterclockwise fashion. The anterior mid-RV was 
the region where the right branch of the superior wavefront met the inferior wavefront, and was 
the latest region to activate in the VT cycle. From here, the VT wavefront slowly propagated 
through the anterior scar (zigzag arrow) and reentered the site of origin. A double-loop pattern 
could be seen in the anterior view of the VT activation map. The lateral LV activated late, because 
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the activation wavefront was blocked at the lateral dense scar. A movie of the activation sequence 
is provided in the attached CD (Movie 2-2). 
For both cases, possible conducting channels that could have facilitated the VT formation 
and conduction were identified and labeled with dashed lines (Figure 2-5, bottom panels). EGMs 
with low voltage, fractionation and late potentials were recorded during SR at and near the site of 
VT origin (Figure 2-5, right of bottom panels),These EGMs reflected local diastolic activities at 
the scar border (zigzag arrows), indicating slow, discontinuous and non-uniform conduction 
through the scar.  
Among 17 patients with a history of spontaneous VT, 8 developed ventricular arrhythmia 
during the ECGI procedure, including non-sustained VT in 6 patients and frequent PVCs in 2 
patients. The site of origin was localized to the dense scar in 2 patients, to the peripheral scar in 5 
patients, and to the non-scar region in 1 patient.  SR EGMs at or near the VT/PVC site of origin 
showed fractionation and LPs in all 8 patients. Only one of these arrhythmias were originated from 
regions with latest SR activation. 
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Figure 2-6: Comparison of the electrophysiological substrate properties between VT 
patients (case) and non-VT patients (control) 
Panel A: Scar burden (scar size as percentage of total epicardial surface area). Panel B: Mean 
unipolar voltage. Panel C: Percentage of fractionated electrograms (EGMs) within total scar, 
dense scar and peripheral scar. Panel D: Prevalence of late potentials (LPs). Percentage of EGMs 
with LPs within total scar, dense scar and peripheral scar. Panel E: Latest activation detected after 
completion of global epicardial activation. Timing is referenced to the latest epicardial activation 
time. Panel F: Number of conducting channels per patient.  P<0.05 is marked with an asterisk. 
 
2.4.3 Comparison of EP Substrate Properties between VT Patients and Non-VT patients 
Figure 2-6 summarizes the differences in the EP substrate between patients with VT (case) 
and patients without VT (control). When controlled for total epicardial surface area, VT patients 
had higher proportion of total scar (51.0±9.3% vs. 36.5±5.4%, p<0.05) and dense scar (29.5±7.3% 
vs. 16.8±6.8%, p<0.05) than non-VT patients (Panel A). There was no significant difference 
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between the groups with respect to the proportion of peripheral scar (21.5±6.6% vs. 19.7±6.1%, 
p=0.43). The mean unipolar voltage (Panel B) was significantly lower in VT patients than in non-
VT patients within the total scar (1.34±0.34 vs. 1.91±0.39 mV, p<0.05), the dense scar (0.91±0.29 
vs. 1.22±0.33 mV, p<0.05) and the peripheral scar (1.97±0.49 vs. 2.58±0.67, p<0.05). Fractionated 
EGMs were observed in every patient. VT patients had higher percentage of fractionated EGMs 
within the total scar (44.1±10.6% vs. 26.8±6.3%, p<0.05), the dense scar (50.8±10.8% vs. 
30.9±7.0%, p<0.05) and the peripheral scar (35.0±13.7% vs. 23.5±9.0%, p<0.05), respectively 
(Panel C). LPs were observed in every patient also. VT patients had higher percentage of EGMs 
with LPs within the total scar (26.8±10.7% vs. 15.8±5.3, p<0.05) and the peripheral scar 
(31.8±12.3% vs. 17.1±6.4%, p<0.05), respectively (Panel D). The 2 groups had similar prevalence 
of LPs within the dense scar (20.4±11.3 % vs. 15.5±8.2%, p=0.17).  If LP was present in an EGM, 
the timing of each late component was measured in reference to the completion of epicardial 
activation. The mean value of latest activation was slightly higher for the VT group (48.8±14.5 vs. 
40.1±12.5 ms, p=0.08), but the difference did not reach statistical significance (Panel E). Voltage 
channels were found in all VT patients and 10 non-VT patients.  VT patients had more channels 
per patient than non-VT patients (3.1±1.2 vs. 1.7±1.2, p<0.05).  
Global repolarization properties were measured and compared between the groups, 
including mean RT, mean ARI, RT dispersions and ARI dispersions. No significant differences 
were found in these parameters (Table 2-2). 
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ECGI-derived Parameters 
Case Group: 
VT Patients 
Control Group: 
Non-VT Patients 
P Value 
 
Scar Size (%) 
Total Scar 51.0±9.3 36.5±5.4 <0.05 
Dense Scar 29.5±7.3 16.8±6.8 <0.05 
Peripheral 
Scar 
21.5±6.6 19.7±6.1 0.43 
Mean Unipolar 
Voltage (mV) 
Total Scar 1.34±0.34 1.91±0.39 <0.05 
Dense Scar 0.91±0.29 1.22±0.33 <0.05 
Peripheral 
Scar 
1.97±0.49 2.58±0.67 <0.05 
Prevalence of 
Fractionated 
EGMs within 
(%) 
Total Scar 44.1±10.6 26.8±6.3 <0.05 
Dense Scar 50.8±10.8 30.9±7.0 <0.05 
Peripheral 
Scar 
35.0±13.7 23.5±9.0 <0.05 
 
Prevalence of 
LP within (%) 
Total Scar 26.8±10.7 15.8±5.3 <0.05 
Dense Scar 20.4±11.3 15.5±8.2 0.17 
Peripheral 
Scar 
31.8±12.3 17.1±6.4 <0.05 
Number of conducting 
channels 
3.1±1.3 1.7±1.2 <0.05 
Latest LP (ms) 48.8±14.5 40.1±12.5 0.08 
Apex-to-base ARI Dispersion 
(ms) 
43.7±9.8 49.3±10.3 0.13 
Apex-to-base RT Dispersion 
(ms) 
55.3±11.8 60.3±10.2 0.22 
RV-to-LV ARI Dispersion (ms) 45.1±8.3 48.5±7.8 0.23 
RV-to-LV RT Dispersion (ms) 59.3±9.5 62.2±10.9 0.43 
Mean ARI (ms) 260.7±18.4 271.2±15.0 0.09 
Mean RT (ms) 336.6±25.3 349.5±22.1 0.14 
Table 2-2: Comparison between VT Patients and Non-VT Patients 
Data are presented as mean±SD. 
 
2.5 Discussion 
2.5.1 Key Findings 
Key findings of this study include: (1) With noninvasive ECGI, the epicardial EP substrate 
associated with MI was characterized by low-voltage and fractionated EGMs, the presence of LPs, 
and altered SR activation pattern; (2) By correlating substrate maps with VT activation maps, 
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critical substrate that supported the VT could be identified; (3) Repolarization abnormalities (such 
as steep dispersion of repolarization) were not present in the substrate, indicating that the 
mechanistic basis for conduction block and VT was structure-based abnormal propagation through 
the scar substrate; (4) Significant differences existed in the EP substrate between VT patients and 
non-VT patients: VT patients had greater epicardial scar burden, lower voltage in the scar, a higher 
prevalence of fractionated EGM and LPs, and more conducting channels. These observations 
explain to a certain extent the role of EP substrate in ventricular arrhythmia and the difference in 
VT incidence between the groups.  Given these findings, the study constitutes a first step towards 
noninvasive arrhythmia risk stratification in ICM patients and pre-procedural guidance for scar-
related VT ablation.  
2.5.2 The EP Scar Substrate 
Following an ischemic event, a complex and progressive remodeling process occurs, which 
changes the EP properties of the heart.25 In heterogeneous post-MI scars, strands of viable, 
excitable myocardial fibers are separated by necrotic myocardium. This creates sites of 
mismatched electrical properties with abrupt increases of electrical load that reduce the safety 
factor for conduction and increase spatial dispersion of excitability.27 These changes can result in 
reduced conduction velocity, discontinuous propagation through the infarct substrate, and regions 
of conduction block - EP properties that promote reentrant arrhythmias. The scar-related abnormal 
EP properties are reflected in low-voltage and fractionated EGMs, as was shown in experimental, 
theoretical and clinical studies.29, 36-38   
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2.5.3 Substrate Mapping and Ablation 
Clinically, ICM patients are studied with invasive catheter mapping. If hemodynamically 
stable VT can be mapped, critical pathways for reentry are identified and ablated. However, 
extended period of VT cannot be tolerated by the majority of patients. Alternatively, substrate 
mapping is performed during SR to identify regions with low-voltage, fractionated and prolonged 
EGMs with LPs, as surrogate targets for ablation.  
Recent substrate-based mapping and ablation studies suggested that complete LP abolition 
is an effective strategy that yields good procedural outcomes.39-42 LPs identify excitable tissue that 
supports very slow, discontinuous conduction and possibly regions of block. Beyond ablation of 
the critical isthmus for VT, this approach requires ablation of all substrates that exhibit LPs to 
achieve scar homogenization. A difficulty with LP mapping is that far-field potentials due to 
depolarization of myocardial tissue remote from the recording electrode could be the source of 
some LPs. In fact, ablating regions with LPs that reflect far-field activity may contribute to failure 
of some substrate guided ablation procedures.39, 41 A recent study combined EGM analysis with 
pace-capture to identify far-field potentials and refine identification of targets for substrate-based 
ablation.43 In the present study, ECGI was used to identify directly far-field potentials in scar 
EGMs and eliminate them from considerations of EGM fractionation.  
2.5.4 ECGI-recorded Scar EGMs and Far-field Deflections 
Previous validation studies demonstrated ECGI’s ability to reconstruct characteristics of 
EGMs associated with post-MI scar in canine experiments.5 In a recent study, ECGI was 
performed in 24 post-MI patients.16 Globally, the abnormal EP substrate on the epicardial aspect 
of the scar was identified. It was characterized by low potentials, and presence of low-voltage 
fractionated EGMs and LPs. The epicardial electrical scar imaged by ECGI co-localized to LGE-
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MRI or SPECT with high accuracy (sensitivity 89%, specificity 85%). The current study dissected 
the scar EP substrate with higher resolution and correlated it with the VT pattern. Because ECGI 
provides panoramic maps of activation times, it can identify far-field potentials in local scar EGMs 
by matching activation times in neighboring EGMs, remote EGMs, or both. This capability for 
direct detection and exclusion of far-field deflections improved the accuracy of EGM fractionation 
analysis. It enabled us to obtain high-resolution maps of voltage, EGM fractionation and LPs 
within the scar, providing detailed spatial EP maps of the scar substrate. By correlating the VT 
activation maps with the high-resolution ECGI images of the EP substrate obtained during SR, 
critical components of the VT circuit could be identified and localized in the scar. These included 
initiation sites, exit sites, and possible conducting channels.   
2.5.5 Scar-related Arrhythmias 
Arrhythmic events in 8 patients were imaged and analyzed. The ECGI-imaged reentry 
circuits were closely related to the EP substrate with EGM fractionation and LPs. The data were 
consistent with the findings from clinical studies,31 in which the isthmus for reentry circuit was 
confined to a region of viable myocardium surrounded by the scar tissue. In 7 of 8 cases, the site 
of origin was located near regions with LPs and low-voltage fractionated EGMs within the scar. 
In one patient, the PVCs were found to originate from a location with a normal EGM magnitude, 
but with fractionation and LP deflections. It is possible that this patient had a mild endocardial scar 
near the PVC site of origin (not detectable by SPECT) and that the ECGI reconstructed epicardial 
unipolar EGMs picked up diastolic activities from intramural locations. Since the epicardium 
remained largely viable, the epicardial EGMs yielded normal magnitude but fractionation and LPs.  
It is noteworthy that the majority of sites critical to reentry exhibited conduction slowing during 
SR based on the activation isochrone map, but only one of them was found in a region with latest 
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SR activation. The observation is consistent with invasive EP studies that suggested that regions 
with conduction delay during SR may be critical for VT maintenance, and that zones with the most 
delayed activation during SR may represent bystander sites irrelevant to the VT circuit.44 
Additionally, part of the inexcitable dense scar possibly served as an inert obstacle determinant of 
the reentry circuit. As shown in Figure 2-5, the wavefront propagated around the dense scar with 
high curvature after exiting from the site of origin.  
2.5.6 Risk Stratification for VT 
Earlier studies45-46 examining the EP substrate associated with MI provided initial insights 
into the differences between VT and non-VT patients. However, they did not provide detailed EP 
information due to limited endocardial sampling points. In a recent study, high-density endocardial 
mapping collected detailed data from the dense scar region, and was used to compare ICM patients 
with and without previous clinical ventricular arrhythmias.35 VT patients were found to have 
markedly larger low-voltage zones, higher density of fractionated EGM, and more conducing 
channels, which were the key markers of the VT substrate. In the current study,  using noninvasive 
ECGI, we compared the epicardial EP substrate between 17 ICM patients presenting with clinical 
VT and 15 ICM patients who had an ICD inserted for primary prevention of SCD and had been 
free from clinical episodes of VT for at least 48 months since ICD insertion.  Despite the similar 
patient characteristics of the 2 groups, the ECGI mapping data revealed that the VT patients had a 
larger extent of total scar and dense scar EP substrate and lower voltage in the scar area. 
Furthermore, the prevalence of EGMs with fractionation and LPs was greater in the VT patients. 
The results add support to previous findings correlating substrate to VT incidence, and emphasize 
the fact that the EP substrate for VT may or may not be present in patients with similar LV function. 
28 
 
Not only the extent of the scar, but also its structural components that underlie spatial properties 
of the EP substrate are important determinants of VT incidence.  
2.5.7 Limitations 
ECGI reconstructs potential maps and unipolar EGMs on the epicardial surface. These 
provide information not only on the epicardial substrate; they reflect properties in the myocardial 
depth as well.2 A previous study demonstrated high correlation between ECGI and imaging with 
MRI and SPECT of transmural scars.16 However, activation isochrone mapping with ECGI is 
limited to the epicardium. Scar-related reentry circuit may involve the endocardium, mid-
myocardium and epicardium. The earliest epicardial activation of VT may not accurately identify 
the location of an endocardial circuit. Importantly, accumulating evidence demonstrates major 
involvement of the epicardium in VT. A recent study predicted scar transmurality and the presence 
of LPs in the epicardium based on the extension and density of the endocardial scar, indicating 
possible requirement of an epicardial ablation procedure.40 The presence of an epicardial substrate 
may be the reason for failure of a subset of endocardial procedures. A combined endocardial-
epicardial ablation strategy is associated with fewer readmissions for VT and repeat ablations 
compared to only-endocardial ablation.47  
The conducting channel in the scar was defined based on preserved EGM voltage during 
SR. This study showed relationship between the conduction channels and the VT entry and exit 
sites. However, slow conduction through the channel during VT cannot be directly mapped by 
ECGI due to limited spatial resolution.  
The extent of the ECGI-derived EP scar was determined by the threshold for EGM 
magnitude. We adapted the threshold from a previous study, which correlated the EP scar to the 
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anatomical scar with good levels of specificity and sensitivity.16 ECGI is also limited in its ability 
to image small amplitude deflections during the repolarization period (T wave). Therefore, the 
maps of LP distribution may not include all the LPs.  
The generalizability of this study is limited by the relatively small number (32) of patients. 
Future large-scale ECGI studies should be conducted to establish the potential of the approach for 
noninvasive arrhythmic risk stratification in ICM patients prior to ICD implantation. 
2.6 Conclusions 
EP mapping with ECGI can overcome certain limitations of catheter mapping. It can 
provide high-resolution maps of post-MI EP substrate together with panoramic maps of activation 
during SR and VT. Being noninvasive, it reduces the procedural risk and can be repeated in follow-
up studies during the remodeling process. Due to its single-beat mapping capability, it can map 
polymorphic and unstable VT. It complements endocardial substrate mapping by providing high-
resolution images of the epicardial EP substrate. To our knowledge, this is the first noninvasive 
EP mapping study in ICM patients that identifies key epicardial EP properties that may account 
for the difference in VT incidence between VT and non-VT patients. It also correlates scar-related 
arrhythmia patterns with high-resolution maps of spatial characteristics of the scar EP substrate 
obtained during SR. With larger-scale studies, ECGI has the potential to become a clinical tool for 
identification of ICM patients at high risk of arrhythmias for ICD indication and for pre-procedural 
guidance of substrate-base ablation.   
 
2.7 Supplemental Material 
2.7.1 Maps of EP Substrate and Activation Sequence for VT Patients 
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Figure 2-7: Patient #1: VT patient; inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display 
the heart in anterior view (left) and inferior view (right). In panel A, epicardial breakthrough is 
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point 
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows 
indicate propagation of the VT wavefront.  
The VT site of origin was localized to the peripheral scar near the inferior base. 
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Figure 2-8: Patient #2: VT patient; inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) VT activation map. All panels display the heart in anterior view (left) 
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. In panel 
F, the VT site of origin is indicated by a plus sign “+”, curved arrows indicate propagation of the 
VT wavefront.  
The VT site of origin was localized to the dense scar near the inferior base. 
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Figure 2-9: Patient #3: VT patient; apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display 
the heart in apical view (left) and inferior view (right). In panel A, epicardial breakthrough is 
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point 
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows 
indicate propagation of the VT wavefront.  
The VT site of origin was localized to the peripheral scar on the anterior wall near the apex. 
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Figure 2-10: Patient #4: VT patient; apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display 
the heart in anterior view (left) and apical view (right). In panel A, epicardial breakthrough is 
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point 
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows 
indicate propagation of the VT wavefront.  
The VT site of origin was localized to the peripheral scar on the anterior wall near the apex.  
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Figure 2-11: Patient #5: VT patient; apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display 
the heart in anterior view (left) and apical view (right). In panel A, epicardial breakthrough is 
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point 
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows 
indicate propagation of the VT wavefront.  
The VT site of origin was localized to the peripheral scar on the anterior wall near the apex. 
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Figure 2-12: Patient #6: VT patient; inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display 
the heart in anterior view (left) and inferior view (right). In panel A, epicardial breakthrough is 
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point 
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows 
indicate propagation of the VT wavefront.  
The VT site of origin was localized to the anterior wall near the apex. EGMs with normal voltage 
but fractionation and late potentials were found in this region.   
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Figure 2-13: Patient #7: VT patient; inferior and infero-lateral myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display 
the heart in inferior view (left) and lateral view (right). In panel A, epicardial breakthrough is 
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point 
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows 
indicate propagation of the VT wavefront.  
The VT site of origin was localized to the dense scar near the lateral left ventricular base.   
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Figure 2-14: Patient #8: VT patient; anterior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) VT activation map. All panels display the heart in anterior view (left) 
and lateral view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. In panel 
F, the VT site of origin is indicated by a plus sign “+”, curved arrows indicate propagation of the 
VT wavefront.  
The VT site of origin was localized to the peripheral scar on the anterior wall near the apex.   
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Figure 2-15: Patient #9: VT patient; inferior and infero-lateral myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block.  
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Figure 2-16: Patient #10: VT patient; inferior and apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left) 
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block.  
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Figure 2-17: Patient #11: VT patient; anterior and apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block. 
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Figure 2-18: Patient #12: VT patient; anterior and apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block.   
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Figure 2-19: Patient #13: VT patient; anterior, lateral and inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in inferior view (left) 
and lateral view (right). In panel A, isochrones are depicted with thin black lines, and black arrows 
point to conduction block. 
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Figure 2-20: Patient #14: VT patient; anterior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block.   
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Figure 2-21: Patient #15: VT patient; lateral, inferior and apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in inferior view (left) 
and apical view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block.   
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Figure 2-22: Patient #16: VT patient; anterior and apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block.   
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Figure 2-23: Patient #17: VT patient; inferior and apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block.   
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2.7.2 Maps of EP Substrate for Non-VT Patients 
 
 
Figure 2-24: Patient #18: Non-VT patient; inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block.   
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Figure 2-25: Patient #19: Non-VT patient; apical, inferior and infero-lateral myocardial 
infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines. 
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Figure 2-26: Patient #20: Non-VT patient; apical and inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left) 
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block.  
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Figure 2-27: Patient #21: Non-VT patient; inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block.   
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Figure 2-28: Patient #22: Non-VT patient; inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left) 
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. 
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Figure 2-29: Patient #23: Non-VT patient; apical and inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left) 
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. 
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Figure 2-30: Patient #24: Non-VT patient; apical and inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left) 
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. 
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Figure 2-31: Patient #25: Non-VT patient; apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left) 
and apical view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. 
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Figure 2-32: Patient #26: Non-VT patient; inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block. 
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Figure 2-33: Patient #27: Non-VT patient; inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left) 
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. 
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Figure 2-34: Patient #28: Non-VT patient; apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block. 
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Figure 2-35: Patient #29: Non-VT patient; inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and inferior view (right). Panels A-E display the heart in anterior view (left) 
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. 
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Figure 2-36: Patient #30: Non-VT patient; anterior, apical and inferior myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left) 
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. 
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Figure 2-37: Patient #31: Non-VT patient; anterior and apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar 
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left) 
and apical view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”, 
isochrones are depicted with thin black lines, and black arrows point to conduction block. 
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Figure 2-38: Patient #32: Non-VT patient; anterior and apical myocardial infarction 
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C) 
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram 
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late 
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right). 
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin 
black lines, and black arrows point to conduction block. 
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2.7.3 Video Files (available in the attached CD): ECGI Activation Movies 
Movie 2-1: The activation sequence during VT for patient #3. 
Movie 2-2: The activation sequence during VT for patient #8.  
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Chapter 3: The Electrophysiological Substrate of Early 
Repolarization Syndrome: Noninvasive Mapping in Patients  
3.1 Abstract 
The early repolarization (ER) pattern is a common ECG finding. Recent studies established 
a definitive clinical association between ER and fatal ventricular arrhythmias. Although the 
underlying mechanisms have been studied at the cellular level, the arrhythmogenic substrate in the 
intact human heart remains poorly understood.  
Using noninvasive Electrocardiographic Imaging (ECGI), we studied 29 ER syndrome 
patients to characterize the electrophysiological (EP) substrate. Seven normal subjects provided 
control data. The abnormal EP substrate in ER syndrome patients has the following properties: (1) 
Abnormal epicardial EGMs characterized by presence of J-waves; (2) Absence of conduction 
abnormalities, including delayed activation, conduction block, or low-voltage and fractionated 
electrograms; (3) Marked abbreviation of ventricular repolarization in areas with epicardial J-
waves. The action potential duration (APD) was significantly shorter than normal (196±19 vs. 
235±21 ms, p<0.05). Shortening of APD occurred heterogeneously, leading to steep repolarization 
gradients compared to normal control (45±17 vs.7±5 ms/cm, p<0.05). Premature ventricular 
contractions (PVCs) were recorded in 2 patients. The PVC sites of origin were closely associated 
with the abnormal EP substrate with J-waves and steep repolarization gradients.   
ECGI identifies regions with steep repolarization gradients caused by localized shortening 
of APD in ER syndrome patients. It also correlates the PVC initiation site with the abnormal EP 
substrate. 
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3.2 Introduction 
The early repolarization (ER) pattern on the ECG is characterized by a J-wave >= 0.1 mV 
in inferior and/or lateral leads.48-50 It resolves during exercise and fast pacing, but accentuates 
during bradycardia. The prevalence of ER pattern in the general population is estimated to range 
between 1% and 13%.48-49, 51  It is thought to be more common in males, young athletes and people 
of African descent.  
Early descriptions of the ER pattern came from cases of hypothermia and hypercalcermia. 
For decades, the ER pattern was recognized as a benign ECG manifestation.52 Since the 1980s, 
this view has been challenged by animal experiments50, 53, case reports54-57 and review articles58-59 
that linked the ER pattern with ventricular arrhythmia. In a recent study with a large cohort of 
patients, the prevalence of ER pattern was significantly higher in patients with idiopathic 
ventricular fibrillation (VF) compared to control subjects.60 This was the first study that provided 
clinical evidence supporting a definitive association between the ER pattern and an increased risk 
of ventricular arrhythmia. Following this study, additional population-based studies provided 
corroborating evidences.49, 61-65  The critical role of the ER pattern in initiating ventricular 
fibrillation has been supported by observations of a consistent and marked J-wave accentuation 
preceding the onset of arrhythmia60, 66 and by electrophysiology (EP) mapping data that showed a 
consistency between the origin of ectopy that initiated VF and the localization of repolarization 
abnormalities.60 
ER has been extensively studied at the molecular and cellular levels.50, 67 Based on the 
prevailing theory, the notch at phase-1 of the epicardial action potential (AP) is more prominent 
than that of the endocardial AP. The transmural voltage gradients give rise to the J-wave on the 
ECG. Further outward shift of the currents can cause loss of the AP plateau. Spatially 
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heterogeneous loss of the AP plateau can lead to reentry (termed “phase-2 reentry”).68 However, 
limitations apply to this model. Extrapolation from cellular processes to tissue and organ behavior 
is difficult, because information at the molecular level is not sufficient to predict and understand 
the complex integrated behavior at higher levels of the physiological system. In particular, 
information on the electrophysiology and arrhythmic behaviors of the intact human heart in vivo, 
where arrhythmias occur, is missing.  
Studies in patients with ER syndrome (ERS) have been so far confined to investigation of 
the ECG characteristics and extrapolating possible mechanisms. However, ECG characteristics 
have been shown to be inadequate measures of underlying repolarization properties.7 Reports of 
EP mapping in patients with ERS provide limited information about the abnormal EP substrate.60, 
69-70 Understanding the mechanism of ER and how it may predispose patients to an increased risk 
of arrhythmias requires detailed mapping of the EP substrate in the intact heart of ERS patients. 
Recent developments in noninvasive Electrocardiographic Imaging 1, 6-7, 10, 13, 16-17 (ECGI; also 
known as ECG mapping, ECM) have demonstrated its ability to obtain high-resolution panoramic 
EP data of epicardial activation, repolarization and their alteration by disease and interventions in 
humans. In the current study, we characterize the epicardial EP substrate in ERS patients based on 
high-resolution ECGI data obtained during sinus rhythm (SR), in an effort to provide insights into 
the mechanism of ER and related arrhythmogenesis.  
3.3 Methods 
3.3.1 Patient Population 
ERS patients from one center in the United States (Washington University) and one center 
in France (Bordeaux University Hospital) were enrolled. The clinical diagnosis is ER pattern on 
the ECG, defined as an elevation of the J-point (J-wave) in at least two leads. The J-wave is 
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manifested either as QRS slurring (a smooth transition from the QRS complex to the ST segment) 
or QRS notching (a positive deflection inscribed on the S wave) in the inferior lead, lateral lead, 
or both. The patients should have at least one of the following: idiopathic ventricular tachycardia 
(VT) or VF, unexplained syncope and familial incidence of unexplained sudden cardiac death. 
Patients with ischemic heart disease and other conditions including long QT syndrome, short QT 
syndrome, Brugada syndrome (BrS) and arrhythmogenic right ventricular cardiomyopathy were 
excluded.  All patients had structurally normal hearts and normal ventricular function. Data from 
seven normal subjects provided normal control.13 Protocols were approved by the Institutional 
Review Boards at both centers; written informed consent was obtained from all patients.  
3.3.2 Noninvasive Mapping 
Details of ECGI methodology were described previously. 1, 6-7, 10, 13, 16-17 Body surface 
potentials were acquired simultaneously using 256 electrodes and a multichannel mapping system. 
Next, the patient underwent thoracic computer tomography with ECG-gating to obtain the 
epicardial geometry and torso electrode positions. The body surface potentials and the patient-
specific heart-torso geometry were processed with ECGI algorithms to reconstruct epicardial 
potentials, unipolar electrograms (EGMs), and maps of epicardial activation and repolarization. 
ECGI has been validated extensively in canine experiments and humans studies. It provides high 
accuracy and high-resolution (2 to 6 mm) panoramic data for noninvasive evaluation of EP 
properties.12  
3.3.3 Data Analysis 
Characteristics of the abnormal EP substrate in ERS patients were analyzed by using data 
recorded during sinus rhythm. The EP mapping data were analyzed for EGM morphology, 
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conduction and repolarization. The ER pattern on epicardial EGMs was defined as J-point 
elevation at the end of QRS. The size of the epicardium with J-waves in the EGMs was measured 
as well (as a percentage of total epicardial surface area). Conduction was evaluated by activation 
time (AT), activation duration (AD), EGM fractionation and voltage. AT was determined by the 
maximal negative slope of the EGM during QRS inscription. All ATs were referenced to the 
beginning of QRS in ECG lead II. Epicardial activation isochrone maps were created from ATs. 
AD was defined as the interval between the earliest and latest AT, considering all epicardial EGMs. 
EGMs with low voltage and fractionation indicate slow, discontinuous and non-uniform 
conduction. EGM magnitude was measured peak-to-peak during the EGM QRS. Fractionation was 
expressed as the number of intrinsic, sharp deflections per EGM. Repolarization was assessed by 
recovery time (RT) and activation-recovery interval (ARI). Local RT was determined from the 
maximal positive slope of the EGM T-wave, which reflects the sum of local AT and local action 
potential duration (APD). Steep RT dispersion has been shown to provide substrate for 
unidirectional block and reentry. ARI was defined as the difference between RT and AT. ARI is 
independent of AT and a surrogate for local APD.71 From the RT map and ARI map, epicardial 
dispersion of repolarization was measured as the maximal difference ΔRT and ΔARI between two 
adjacent EGM sites on the epicardium. Epicardial RT and ARI gradients (ΔRT/Δx and ΔARI/Δx) 
were computed through division by the distance Δx between the two adjacent sites. 
 
3.3.4 Statistical Analysis: 
All continuous data are presented as mean±SD. Continuous variables were analyzed by 
unpaired t-test. The Satterthwaite modified t-test was used for variables with unequal variances. 
The Mann-Whitney U test was used for variables with non-normal distribution. All tests with 
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P<0.05 were considered statistically significant. Statistical analysis was performed by using SPSS 
v19.  
Patient 
ID 
Age Gender 
Previously 
Aborted 
SCD/ 
Documented 
VT or VF 
Syncope 
Family 
History 
of 
SCD/ 
ERS 
ICD 
Implant 
ECG Leads with ER 
Inferior 
Leads 
Lateral 
Leads 
ER-1 27 M + - + + 
II, III, 
aVF 
V4, V5, V6 
ER-2 60 F - + + - II, III  
ER-3 64 M + - - + II I, V5, V6 
ER-4 24 M + + - +  
I, V4, V5, 
V6 
ER-5 49 M + - - - II I 
ER-6 23 M - + - - 
II, III, 
aVF 
V4, V5, V6 
ER-7 59 M + - - + II, aVF V4, V5, V6 
ER-8 24 M - - + - 
II, III, 
aVF 
V5, V6 
ER-9 48 F + + + +  V5, V6 
ER-10 25 M - + - - II V5, V6 
ER-11 31 M - - + -  V4, V5, V6 
ER-12 28 M + + + + 
II, III, 
aVF 
 
ER-13 25 M + - + - II, aVF V5, V6 
ER-14 37 M + - - - 
II, III, 
aVF 
I, V4, V5, 
V6 
ER-15 35 M - + - - 
II, III, 
aVF 
V4, V5, V6 
ER-16 34 M + + - - II I, V5, V6 
ER-17 65 M - - + - 
II, III, 
aVF 
V4, V5 
ER-18 41 M + - - -  V4, V5 
ER-19 48 M - + - -  V5, V6 
ER-20 27 M - + - - II, III  
ER-21 24 M - + - - II V5, V6 
ER-22 58 M + - - +  V4, V5 
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ER-23 49 M + + - + 
II, III, 
aVF 
V4, V5, V6 
ER-24 21 M + - - - 
II, III, 
aVF 
I, V4, V5, 
V6 
ER-25 40 M + + - - II, III 
I, V4, V5, 
V6 
ER-26 26 F - + - - 
II, III, 
aVF 
V4, V5, V6 
ER-27 31 M - - + - 
II, III, 
aVF 
V5, V6 
ER-28 23 M + - + + 
II, III, 
aVF 
 
ER-29 22 M + - - +  V4, V5, V6 
Table 3-1: Clinical Characteristics of the ERS Patients 
 
3.4 Results: 
Twenty-nine ERS patients (26 men, 3 women) were enrolled in this study. Seventeen 
(59%) had previous aborted SCD or arrhythmic events (idiopathic VT/VF), 10 of which received 
implantable cardioverter-defibrillator (ICD). Fourteen (48%) experienced unexplained syncope. 
Ten (34%) had a family history of SCD or ERS. Detailed characteristics for individual patient are 
provided in Table 3-1. 
3.4.1 EGM Characterization and Localization  
Figure 3-1 shows epicardial EGM characteristics and localization for representative 
examples in 3 ERS patients. Patient ER-11 was an asymptomatic patient with a family history of 
sudden death. He had ER pattern in lateral leads.  Patient ER-14   experienced previously aborted 
sudden death, and had ER pattern in inferior leads and lateral leads. Patient ER-20 did not have 
clinical arrhythmic events, but experienced unexplained syncope. His ER pattern was found in 
inferior leads. Data from a normal subject is provided for reference. Epicardial J-wave was 
observed in EGMs from all 25 ERS patients (0.68±0.25 mV vs. 0 mV in control, p<0.05); 6 in the 
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anterior wall, 19 in the lateral wall and 23 in the inferior wall (most patients had epicardial J-wave 
in multiple locations). The proportion of epicardium that presented J-wave ranges from 23% to 
57%, with a mean value of 39%±9%. EGMs with abnormal low-voltage and fractionation were 
not found in any ERS patient.  
 
Figure 3-1: Epicardial J-wave Distribution and Magnitude  
Abnormal epicardial EGMs with a J-wave that resemble the ER pattern (terminal-QRS notch or 
slurring) on the surface ECG are observed in ERS patients, but not seen in normal subjects. 
Example maps of epicardial J-wave magnitude in 3 ERS patients are shown. The maps are shown 
in anterior view and inferior view for each subject. The locations of epicardial J-waves are ER-
11: lateral and apical left ventricle (LV); ER-14: lateral and inferior LV; ER-20: lateral and 
inferior LV. Inset: representative EGMs with a J-wave (QRS only) in ERS patients (Panels B, 
C, D) and EGMs from corresponding locations in the normal control subject (Panel A). LA = 
left atrium; LV = left ventricle; RA = right ventricle; RV = right ventricle. 
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3.4.2 Epicardial Activation 
Figure 3-2 shows ECGI epicardial activation isochrone maps for a control subject and 3 
ERS patients (same patients as in Figure 3-1). The epicardial activation pattern during SR in ERS 
patients was characterized by a normal epicardial breakthrough (white asterisks) in the right 
ventricle (RV). The excitation wavefront spread uniformly and rapidly to activate both ventricles. 
The left ventricular (LV) base was the latest region to activate. The activation pattern was not 
affected by the presence of the J-wave: regions of slow conduction (isochrone crowding) or 
 
Figure 3-2: Activation Isochrone Maps  
Examples of activation during sinus rhythm (SR) are shown for a normal control subject and 3 
ERS patients. The maps are shown in anterior view and inferior view for each subject. ERS 
patients and the normal subject have similar activation patterns. After breakthrough in the 
anterior right ventricle (asterisk), the wavefront propagates uniformly to activate both ventricles. 
The LV base is the latest region to activate. Conduction block and slow conduction were not 
observed in the ERS patients. 
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conduction block (adjacent activation times differ by more than 50 ms) were not found in ERS 
patients. A similar activation sequence was observed in the normal control subjects, as well as in 
the isolated human heart from individuals with no history of cardiac disease.72 AD, the time needed 
for activation of both ventricles, was 54±7 ms for ERS patients, comparable with 47±9 ms for 
normal control. 
 
Figure 3-3: Recovery Time (RT) Maps  
Examples of epicardial RT during SR are shown for a normal control subject and 3 ERS patients. 
Maps are shown in anterior view and inferior view for each subject. ERS patients have regions 
with abnormally short RT (dark blue). White arrows in Panels B-C point to regions with steep 
RT gradients. 
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Figure 3-4: Activation-recovery Interval (ARI) Maps 
Panels A to D: ARI maps for a normal control subject and 3 ERS patients. Maps are shown in 
anterior view and inferior view for each subject. ERS patients have regions with abnormally short 
ARI (dark blue). White arrows in Panels B-C point to regions with steep ARI gradients. Panel E 
shows the ECGI reconstructed electrograms (EGMs) from two adjacent locations for each ERS 
patient. Location 1: prominent J-wave and short ARI; location 2: absence of J-wave and normal 
ARI. There is a steep gradient of repolarization across these two locations. The time instances of 
activation (AT; black square), recovery (RT; red square) and corresponding ARIs are indicated.   
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3.4.3 Epicardial Repolarization 
Representative maps of RT (Figure 3-3) and ARI (Figure 3-4) from a normal subject and 
3 ERS patients (same patients as in Figure 3-1) demonstrate marked local changes in repolarization 
in ERS patients compared with normal control. Abnormal repolarization was observed primarily 
in regions with a prominent J-wave. Steep epicardial RT gradients and ARI gradients occurred 
mostly at the border of regions where J-wave were present (Figure 3-3, Panel B-D, white arrows).  
Figure 3-4E shows EGMs with prominent J-wave (location 1) and EGMs without J-wave from an 
adjacent location (location 2) for 3 ER patients. Take patient ER-11 for example, ATs at location 
1 and 2 were similar (AT(1) =66 ms, AT(2) =61 ms), but repolarization dispersion was observed 
between the two locations: ΔRT was 65 ms (RT(1) =232 ms, RT(2) =297 ms) and ΔARI was 70 
ms (ARI(1) =166 ms, ARI(2) =236 ms). This resulted in steep gradients of RT and ARI (ΔRT/Δx 
=43 ms/cm; ΔARI/Δx =46 ms/cm), much steeper than those of control (typically 5~8 ms/cm and 
4~10 ms/cm, respectively, in the same region). Patients ER-14 and ER-20 also had shortened RT 
and ARI, as well as increased gradients of RT and ARI, but the location of abnormal repolarization 
varied.  
Table 3-2 summarizes the ECGI-derived parameters. Compared with normal control, ERS 
patients had shortened RT (223±28 vs. 265±30 ms, p<0.05) and ARI (196±19 vs. 235±21 ms, 
p<0.05), increased repolarization dispersion ΔRT (52±15 vs.18±14 ms, p<0.05) and ΔARI (53±15 
vs. 16±10 ms, p<0.05) and increased repolarization gradients ΔRT/Δx (48±18 vs. 8±6 ms/cm, 
p<0.05 )  and ΔARI/Δx (45±17 vs. 7±5 ms/cm, p<0.05).  
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Parameters 
Normal 
Control 
(N=7) 
ERS Patients 
(N=29) 
P 
value 
J-wave Magnitude 
(mV) 
0 0.68±0.25 P<0.05 
AD (ms) 47±9 54±7 NS 
Mean RT (ms) 265±30 223±28 P<0.05 
ΔRT (ms) 18±14 52±15 P<0.05 
ΔRT/Δx (ms/cm) 8±6 48±18 P<0.05 
Mean ARI (ms) 235±21 196±19 P<0.05 
ΔARI (ms) 16±10 53±15 P<0.05 
ΔARI/Δx (ms/cm) 7±5 45±17 P<0.05 
Table 3-2: Comparison of ECGI Parameters between ERS Patients and Normal Subjects 
Data are presented as mean±SD. AD = activation duration; ARI = activation-recovery interval; RT 
= recovery time; NS = not significant.  
 
3.4.4 Ventricular Arrhythmias 
Premature ventricular contractions (PVCs) were recorded in two patients, ER-1 and ER-
11. Figure 3-5 shows substrate maps (J-wave and ARI) and PVC activation maps for patients ER-
1 and ER-11. Panel A shows that in patient ER-1, a large portion of epicardium (54%) was affected 
by abnormal EGMs with J-waves, including anterior RV, anterior LV, lateral LV, apical LV and 
inferior LV (not shown). In patient ER-11, about 32% of the epicardium had J-waves in the EGMs, 
located in the antero-lateral and apical LV. Panel B shows that in patient ER-1, the anterior RV 
had the shortest ARI (about 140 ms), and the majority of LV had ARI less than 180 ms, 
significantly below the normal range. Patient ER-11 had shortened ARI (about 160 ms) in the 
antero-lateral and apical LV. Panel C shows the PVC activation patterns. In patient ER-1, the PVC 
originated from the apical LV region, then propagated towards the basal RV. In patient ER-11, the 
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PVC initiation site was located in mid anterior LV near the septum. The inferior LV was the latest 
region to activate during a PVC. In both cases, locations of the EP substrate with abnormal EGMs, 
shortened ARIs and steep ARI gradients correlated with the PVC sites of origin. 
 
Figure 3-5: The electrophysiological substrate in relation to premature ventricular 
contractions (PVCs) 
Panel A: Epicardial J-wave magnitude and Panel B: Activation-recovery interval (ARI) maps 
during SR. Panel C: PVC activation map. Each panel shows the maps for 2 patients, ER-1 (left) 
and ER-11 (right). The hearts are displayed in anterior view and lateral view. Inset: abnormal 
electrograms (EGMs) with J-waves during SR from the PVC sites of origin. The PVC initiation 
sites are indicated by plus signs “+”. Note that an EP substrate with abnormal EGMs, shortened 
ARIs and steep ARI gradients correlated with the PVC site of origin in both cases. 
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3.5 Discussion: 
This is the first noninvasive mapping study in ERS patients that identifies key epicardial 
EP properties that may account for the arrhythmogenicity in this syndrome. High-resolution 
panoramic mapping was essential for characterizing the properties of the EP substrate; it was made 
possible by noninvasive ECGI. The results indicate that ERS patients present with regions of 
abnormal EP substrate with the following properties: (1) Abnormal epicardial EGMs characterized 
by the presence of a J-wave, which is consistent with the ECG-based clinical phenotype; (2) 
Absence of conduction abnormalities, such as delayed activation, EGMs with low voltage and 
fractionation; (3) Marked abbreviation of ventricular repolarization in areas with epicardial J-
waves, leading to steep repolarization gradients.   
The cellular mechanisms underlying the ER pattern and arrhythmogenesis have been 
studied using canine ventricular wedge preparation.67-68 Because the expression of transient 
outward current (Ito) is highest in the epicardium and diminishes transmurally towards the 
endocardium, a phase-1 notch is present in epicardial AP, but not in endocardial AP. The 
transmural voltage gradient during an early phase of ventricular repolarization registers as J-wave 
on the ECG. Under pathological conditions, in the presence of an intense Ito or with a greater 
outward shift of currents active at the end of phase 1 of the AP (increase in IK-ATP, IK-ACh or decrease 
in ICa-L or late INa), the membrane is repolarized prematurely, losing the epicardial AP plateau, 
which leads to marked abbreviation of the AP. The loss of the AP plateau in epicardium but not 
endocardium creates transmural voltage gradients during phase 2 and 3 of the AP that manifest as 
a prominent ST-segment elevation.50 Spatially heterogeneous loss of the AP plateau can generate 
substrate with steep repolarization gradients that may facilitate the development of phase 2 reentry 
and polymorphic VT/VF.68 A recent study in a canine LV wedge preparation showed that 
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accentuation of the AP notch in the LV epicardium gave rise to the ER pattern.73 This 
repolarization abnormality was accentuated by increased vagal tone, and normalized by 
administration of isoproterenol and quinidine. The levels of Ito was higher in the inferior LV wall, 
which may account for the greater sensitivity to development of VT/VF in this region.  
Since the link between the ER pattern on the ECG and fatal cardiac arrhythmias has been 
confirmed,60 numerous studies have been conducted in an effort to stratify risks of ventricular 
arrhythmias in the ER population. Risk stratification has profound clinical importance, given the 
prevalence of the ER pattern in the general population. Importantly, young otherwise healthy 
individuals with ER may be more vulnerable to idiopathic VF.74-75 Currently, surface ECG is the 
only tool available and the identification of ERS patients at risk remains extremely challenging. 
Surface ECG markers, including the amplitude and distribution of the J-wave, morphology of the 
ST segment and the presence of ventricular ectopy have been demonstrated to predict arrhythmic 
risks. A higher J-wave amplitude is associated with increased risk of sudden death.49, 65  A lateral 
distribution of ER does not portend risk, whereas an inferior and global distribution of ER predicts 
an increased risk of arrhythmic death.49, 60, 63  A horizontal or descending ST segment also portends 
a higher risk of sudden death.65, 76-77 Of note, although these ECG markers are associated with an 
increased relative risk of arrhythmia in the ER population, they have very limited utility in 
predicting the absolute risk in the general population, due to the extraordinarily low incidence of 
idiopathic VF.78 A recent study investigated the role of EP studies in risk stratification in ERS 
patients.79 Results indicate that VF inducibility does not have a role in risk stratification in ERS 
patients; it neither predicts arrhythmic risks, nor correlates with the ECG markers discussed earlier. 
Better understanding of the clinical entity is the key for development of diagnostic and risk 
stratification tools.  
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The fact that a significant number of individuals with ERS had a family history of sudden 
cardiac death suggests a genetic basis for this syndrome. ERS has been associated with mutations 
in 7 genes, including mutations in KCNJ8 and ABCC9 that encode the IK-ATP channel,
80-82 
mutations in CACNA1C, CACNB2 and CACNA2D1 associated with the ICa-L channel,
83 and a 
mutation in SCN5A that affects INa.
84  Interestingly, the IK-ATP channel is inactive in non-ischemic 
ventricular myocardium; it activates and becomes increasingly outward with decreasing levels of 
ATP.85  IK-ATP is expressed in myocytes at very high levels, similar to that of INa.
86-87 Experimental 
and simulation studies consistently showed that opening of a small percentage of IK-ATP channels 
(0.7% -1.2%) may shorten the APD by 50%.86, 88 Mutations can cause IK-ATP channels to open at 
normal ATP levels, thereby causing early AP repolarization. As discussed above, heterogeneous 
APD abbreviation can provide both the substrate and trigger that precipitate VF. 
The current study investigated whether the electrocardiographic manifestation of ER 
reflects abnormal repolarization or late potentials associated with delayed conduction in certain 
regions of the heart. Conduction delay is a common cause for notching of the terminal QRS 
complex, especially in patients with a history of myocardial infarction. Asynchronous activation 
can also create voltage gradients, causing ST-segment elevation. The canine ventricular wedge 
model did not represent abnormal conduction in the myocardium; it investigated the mechanism 
of ER pattern in the setting of abnormal repolarization alone. The role of conduction abnormalities 
in the ER pattern and arrhythmogenesis was not explored in that model.   
As the results show, all ERS patients had a normal activation pattern during SR. The mean 
ventricular AD (Table 3-2) was comparable with normal control. In addition to AT and activation 
pattern, the morphology of EGMs was also examined in detail. Experimental and clinical studies 
have shown that low-amplitude and fractionated EGMs reflect slow, non-uniform and 
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discontinuous conduction through a substrate with structural heterogeneity.38 ECGI is able to 
reconstruct such EGMs with high accuracy and has been used to study the EP substrate associated 
with structural abnormalities including post-MI and BrS patients.5, 8, 16, 20 EGMs with abnormal 
low-amplitude and fractionation were not found in ERS patients. Catheter mapping in ERS patients 
did not show abnormalities during ventricular depolarization that registered with the terminal QRS 
notch or slurring, confirming that the ECG J-wave was related to repolarization.69 Taken together, 
these findings indicate that ventricular conduction is normal in ERS patients, and that the J-wave 
on the ECG is not likely to be caused by abnormal conduction.  
Figure 3-3 and Figure 3-4 demonstrate that there is significant regional abbreviation of the 
AP (based on reconstructed ARIs) on the ventricular epicardium of ERS patients compared with 
normal control. As shown in Figure 3-4E, in regions with abnormal EGMs, the epicardial J-wave 
is followed by shortening of RT. These regions were located in close proximity to regions with 
relatively longer RT. The regional differences in RT gave rise to steep RT gradients. Given the 
fast and uniform conduction, the difference in ATs between two adjacent locations is too small to 
account for the difference in RTs. Thus, RT and RT dispersion are primarily determined by ARI 
and ARI dispersion, independent of conduction.  With ARI being the surrogate for local APD, 
shortened ARI suggests abbreviated AP. The formation of regions with steep gradient of 
repolarization is caused by spatially heterogeneous abbreviation of the AP over short distances. In 
contrast, the apex-to-base ARI dispersion (about 42 ms) and inter-ventricular ARI dispersion 
(about 32 ms) result in much shallower gradients  in normal subjects.13  Results from this study 
are consistent with a previous case report that presented preliminary data from 2 ERS patients 
mapped by ECGI.15 
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Although ECG markers are currently the only noninvasive tool to identify high-risk ERS 
patients, it lacks sensitivity and specificity. Each ECG electrode on the body surface records an 
electric signal that reflects integrated activity over the entire heart. Therefore, spatial relationships 
in the heart are lost in the body-surface ECG. It has been shown that body-surface measures do 
not adequately reflect myocardial dispersion of repolarization.7  This limitation is overcome by 
ECGI: it provides physiologically relevant information about myocardial repolarization by 
reconstructing the actual spatial properties and dispersion on the surface of the heart. 
ER and BrS are often collectively referred to as “J-wave syndromes”, because the two 
conditions share similar ECG characteristics and a number of clinical features. Both are associated 
with vulnerability to fatal VT/VF in young adults without apparent structural heart disease, and 
have dominance in males.89   The J-wave and associated ST-segment elevation are accentuated 
before the arrhythmic event, and VF is often initiated during bradycardia. Their responses to 
quinidine and isoproterenol are ameliorative (normalization of the J-wave and inhibition of 
VT/VF).68  Nevertheless, there are several key characteristics that distinguish ERS from BrS, 
suggesting different underlying mechanisms for the ECG phenotype and arrhythmogenesis. 
Moderate structural abnormalities (RV interstitial derangement), though undetectable by 
noninvasive clinical imaging, have been found in endomyocardial biopsies of BrS patients, as well 
as in the explanted heart of a BrS patient. 90-91  In a recent study, ECGI was performed in 25 BrS 
patients.20  Altered or delayed epicardial activation in the RVOT was found in 20 patients. EGMs 
with abnormally low voltage and fractionation were found in all patients. Prolonged repolarization 
and steep repolarization gradients were also observed. These findings demonstrate the coexistence 
of conduction and repolarization abnormalities in BrS. The abnormal EP substrate was confined 
to the RVOT. In contrast, the wide-spread distribution of J-waves in ERS patients indicates that 
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the EP substrate may not be localized to a specific region of the heart. The current study identifies 
additional differences between ERS and BrS. Conduction delays and EGMs indicative of slow 
discontinuous conduction were not found in ERS patients. The location and size of the abnormal 
EP substrate varied among ERS patients. Instead of ARI prolongation in BrS patients, shortened 
ARIs were observed in ERS patients during baseline SR.  
There is a paucity of EP mapping data of ERS-related arrhythmias, given the small number 
of ERS patients who have experienced aborted sudden cardiac death. Catheter mapping was 
performed in 8 ERS patients with a history of idiopathic VF.60 In 6 patients with ER pattern only 
in the inferior ECG leads, all ectopies were mapped to the inferior ventricular wall.  In 2 patients 
with ER pattern in both inferior and lateral leads, ectopy originated from multiple locations. In the 
current study, PVCs were recorded in 2 patients. The PVC sites of origin were located in an 
epicardial region with marked J-waves and short ARIs.  A recent study using ECGI in an ERS 
patient during VF identified VF rotors in the inferior-lateral LV wall.92  These data suggest that 
the EP substrate in the inferior and lateral LV plays an important role in the development of 
arrhythmias. If a triggering ectopy interacts with a susceptible substrate of steep repolarization 
dispersion at the right time, direction and orientation, unidirectional block and reentrant arrhythmia 
could be initiated.  
Limitations: 
The control data were not obtained at the time of this study; they were recorded previously 
with the same ECGI methodology.  
Being the first ECGI study of ERS patients, its generalizability is limited by the relatively 
small number of patients. It does not differentiate between subgroups (e.g. symptoms and 
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genotype) within the population. Future large-scale ECGI studies should be conducted to establish 
the potential of the approach for noninvasive arrhythmic risk stratification in ER patients. 
Changes in heart rate are known to affect the ER pattern on the ECG, but this protocol was 
not adopted in this study. Future studies will explore how the patterns of repolarization dispersion 
respond to heart rate changes.  
Several drugs (including quinidine, isoproterenol, milrinone, and cilostazol) have been 
shown to have ameliorative effects on the ER pattern. Future studies should characterize drug 
effects on activation and repolarization patterns. The changes in activation and repolarization could 
provide additional information on the EP substrate and arrhythmia mechanisms associated with 
ERS.  
3.6 Conclusions: 
Noninvasive ECGI revealed the presence of abnormal EP substrate in ERS patients, 
characterized by a regional distribution of epicardial J-waves and shortening of APD. 
Heterogeneous APD shortening leads to steep repolarization gradients. This defines a substrate 
susceptible to reentrant arrhythmias, not detectable by the surface ECG. Conduction abnormalities 
were not present. PVC sites of origin correlated with regions of J-wave presence and steep 
repolarization gradients, the abnormal EP substrate mapped during SR. 
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Chapter 4: The Cardiac Electrophysiologic Substrate 
Underlying the ECG Phenotype and Electrogram Abnormalities in 
Brugada Syndrome Patients  
4.1 Abstract 
Brugada syndrome (BrS) is a highly arrhythmogenic cardiac disorder, associated with an 
increased incidence of sudden death. Its arrhythmogenic substrate in the intact human heart 
remains ill-defined.  
Using noninvasive ECG imaging (ECGI), we studied 25 BrS patients to characterize the 
electrophysiologic substrate, and 6 patients with right bundle branch block (RBBB) for 
comparison. Seven normal subjects provided control data. Abnormal substrate was observed 
exclusively in the right ventricular outflow tract (RVOT) with the following properties (compared 
to normal controls; p<0.005): (1)ST-segment elevation (STE) and inverted T-wave of unipolar 
electrograms (EGMs) (2.21±0.67 vs. 0 mV); (2)delayed RVOT activation (82±18 vs. 37±11 ms); 
(3)low amplitude (0.47±0.16 vs. 3.74±1.60 mV) and fractionated EGMs, suggesting slow 
discontinuous conduction; (4)prolonged recovery time (RT; 381±30 vs. 311±34 ms) and 
activation-recovery intervals (ARIs; 318±32 vs. 241±27 ms), indicating delayed repolarization; 
(5)steep repolarization gradients (ΔRT/Δx= 96±28  vs. 7±6 ms/cm, ΔARI/Δx= 105±24 vs. 7±5 
ms/cm) at RVOT borders. With increased heart rate in 6 BrS patients, reduced STE and increased 
fractionation were observed. Unlike BrS, RBBB had delayed activation in the entire RV, without 
STE, fractionation, or repolarization abnormalities on EGMs. 
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The results indicate that both, slow discontinuous conduction and steep dispersion of 
repolarization are present in the RVOT of BrS patients. ECGI could differentiate between BrS and 
RBBB. 
4.2 Introduction 
Brugada syndrome (BrS) is an inherited disorder, affecting predominantly males in their 
40s93 and associated with an increased incidence of sudden cardiac death (SCD). It presents with 
ECG expression of atypical right bundle branch block (RBBB) pattern and ST-segment elevation 
(STE) in leads V1-V3.93-94  It is estimated that BrS causes approximately 20% of SCD in cardiac 
patients with structurally normal hearts.93 Understanding its pathophysiological mechanisms is 
essential for improving risk stratification, diagnosis and treatment to prevent SCD.  
BrS is considered a primary electrical cardiac disease, since no structural anomalies are 
detected by conventional imaging.  Up to 30% of patients test positive for mutations in the SCN5A 
gene,93 which causes a loss-of-function of the cardiac sodium channel (INa).  A Brugada ECG 
pattern can be provoked, in some affected patients with a normal baseline ECG pattern, by 
administration of INa blockers.  
There are two leading hypotheses for mechanisms underlying BrS phenotype and 
arrhythmias. (1) The abnormal repolarization hypothesis (based on the canine wedge 
preparation):95-97  Phase-1 notch is present in epicardial action potentials (AP) due to a high 
density of transient outward current (Ito), but absent in endocardial APs (low Ito  density). A reduced 
INa in BrS exaggerates the phase-1 notch preferentially in right ventricular outflow tract (RVOT) 
epicardium, where Ito is expressed with maximal density. The resulting voltage gradients give rise 
to STE on the ECG. Further outward shift of the balance between INa and Ito can repolarize the 
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membrane during phase-1 below the voltage range for L-type calcium channels (ICa-L) activation. 
When ICa-L fails to activate, the AP loses its plateau (dome). Spatially heterogeneous loss of the 
AP plateau in the RVOT can lead to reentry (termed “phase-2 reentry” by Antzelevitch and 
colleagues). (2) The abnormal conduction hypothesis (based on whole–heart studies in BrS 
patients):90, 98-99 Impaired INa in structurally deranged tissue causes slow discontinuous AP 
propagation. Asynchronous activation can promote reentrant arrhythmias and create voltage 
gradients, causing STE and fractionation on the ECG. Data from catheter mapping98 showed that 
delayed conduction and abnormal electrograms (EGMs) with low voltage and fractionated late 
potentials (reflecting slow discontinuous conduction) were exclusively localized in the anterior 
aspect of the RVOT epicardium. Catheter ablation in this area normalized the Brugada ECG and 
prevented ventricular tachycardia (VT). The pathophysiological mechanisms of the abnormal ECG 
and arrhythmia in BrS are still a subject of debate. 
While much is known at the molecular and cellular scales, understanding the cause of the 
BrS ECG pattern and associated arrhythmias requires detailed characterization of the 
electrophysiologic (EP) substrate in the intact hearts of BrS patients. This requires high resolution, 
panoramic EP mapping of the ventricles and cannot be achieved with invasive catheter mapping. 
The recent development of noninvasive mapping with Electrocardiographic Imaging (ECGI) 
allowed us to obtain the first high resolution panoramic EP data from BrS patients, including up 
to 1500 unipolar epicardial EGMs and epicardial maps of activation and repolarization.5-6, 10, 13, 16, 
19, 100 Based on these data recorded during sinus rhythm (SR), we characterized the EP substrate in 
BrS patients in an effort to provide insight into the mechanistic origin of the BrS phenotype. The 
results show that both, repolarization and structurally-based conduction abnormalities coexist in 
hearts of BrS patients.  We also compared the BrS EP substrate to non-BrS RBBB (generally 
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considered benign) to determine whether the substrate is specific to BrS, and whether ECGI can 
differentiate between these two pathologies with similar ECGs.  
4.3 Methods 
4.3.1 Patient Population 
Twenty-five BrS patients from two centers in the United States and one in France were 
enrolled. The BrS diagnosis was based on the consensus criteria93 and was the basis for patient 
recruitment. Beyond the consensus criteria, pregnant women and children were excluded. Patient 
demographic data are provided in Table 4-1. Six RBBB patients with a prolonged QRS>120ms 
were studied for comparison. All BrS and RBBB patients had no evidence of structural heart 
disease on echocardiography or MRI. Data from seven normal subjects13 provided normal control. 
Cumulative subject characteristics are provided in Table 4-2. Protocols were approved by the 
Institutional Review Boards at the three centers; written informed consent was obtained from all 
patients.  
4.3.2 Noninvasive Mapping 
ECGI methodology was described previously5-6, 10, 13, 16, 100 (Figure 4-1). Briefly, torso 
surface ECG potentials, recorded simultaneously from 250 electrodes, were combined 
mathematically with patient-specific heart-torso geometry from ECG-gated computed tomography 
(CT) to construct epicardial potentials, unipolar EGMs, and maps of epicardial activation and 
repolarization. Bipolar EGMs were constructed for fractionation analysis. The method was 
validated extensively for reconstruction of EGMs,5-6 activation10, 13  and repolarization.6, 13  
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Patient 
ID 
Age Gender 
SCN5A 
Mutation 
Previously 
Aborted 
SCD 
Syncope 
Family History 
of SCD/ 
Brugada ECG 
ICD 
Implanted 
ICD 
Therapy 
ECG Leads 
with STE 
BrS-1 34 M - + - - + + V1, V2, V3 
BrS-2 53 M + + - + + - V1, V2 
BrS-3 54 M + - + + - - V1 
BrS-4 48 M + - + + - - V1, V2 
BrS-5 52 M + - + + - - V1, V2 
BrS-6 62 F + - - + - - V1 
BrS-7 43 M - - - - - - V1, V2 
BrS-8 41 M + - + - - - V1, V2, V3 
BrS-9 66 M - - - - - - V2 
BrS-10 29 M - + - + + - V1, V2, V3 
BrS-11 44 M + - - + - - V1, V2 
BrS-12 45 M - - - - - - V1, V2 
BrS-13 78 M N/A + - - - - V1 
BrS-14 60 M - + - - + + V2 
BrS-15 31 M + - - - - - V1, V2 
BrS-16 30 M N/A - - + - - V1, V2, V3 
BrS-17 54 F - - + + - - V1, V2 
BrS-18 63 M + + - + + - V2, V3 
BrS-19 61 M N/A - + - + - V1 
BrS-20 45 M N/A + - - + + V1, V2, V3 
BrS-21 39 M N/A + - - + + V1, V2 
BrS-22 48 M + + - - + - V1, V2 
BrS-23 19 M + + - - + - V1 
BrS-24 45 M N/A - + + - - V1 
BrS-25 49 M N/A - - + + - V1, V2 
Table 4-1: BrS Patient Demographics 
ICD = Implantable Cardioverter Defibrillator;  SCD = Sudden Cardiac Death;  STE = ST Segment 
Elevation. 
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 BrS (n=25) RBBB (n=6) Control (n=7) 
Age (Year) 48±13 41±12 28±7 
Male 23 (92%) 6 (100%) 4 (57%) 
SCN5A Mutation 11 (44%) N/A N/A 
Previously Aborted SCD 10 (40%) 0 (0%) 0 (0%) 
Syncope 7 (28%) 0 (0%) 0 (0%) 
Family History of SCD or  
 Brugada ECG 
12 (48%) 0 (0%) 0 (0%) 
ICD Implant 11 (44%) 0 (0%) 0 (0%) 
ICD Therapy 4 (16%) 0 (0%) 0 (0%) 
Table 4-2: Cumulative Subject Characteristics 
Data are presented as mean±SD or number (percentage) of patients. ICD = Implantable Cardioverter 
Defibrillator;  SCD = Sudden Cardiac Death.  
 
 
Figure 4-1: ECGI Procedure and Parameters 
Panel A: The noninvasive ECGI procedure. Body surface potential recordings (250 electrodes) 
and gated, non-contrast thoracic computed tomography (CT) scan are processed mathematically 
to obtain epicardial potentials, 1500 unipolar electrograms, and maps of epicardial activation and 
repolarization. Panel B: The right ventricular outflow tract (RVOT) region in one patient’s heart 
(shown in red) as determined from CT images. This representative image serves as an example. 
Panel C: Temporal fiducial points on electrograms. AT: activation time; RT: recovery time; ARI: 
activation recovery interval. 
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Spatial properties of the EP substrate were determined by dividing the epicardium into 6 
segments based on CT images (the RVOT is depicted in Figure 4-1B). EGMs from valvular regions 
were excluded.  On average, 1154 EGMs per patient were used for analysis. 
EGMs were evaluated for morphology, magnitude and fractionation.  EGM Brugada 
morphology was defined as STE followed by T-wave inversion. EGM magnitude (EMM) was 
measured peak-to-peak during the EGM QRS; for fractionated EGMs, the measurement was 
confined to the fractionated segment.  Fractionation was expressed as number of low-amplitude 
deflections per EGM and displayed on epicardial EGM deflection maps (EDMs).16 For the 
fractionation analysis, bipolar EGMs were approximated by time derivatives of unipolar EGMs.    
Local activation time (AT, referenced to beginning of QRS in ECG lead II) was determined 
by the maximal negative slope of the EGM during QRS inscription (Figure 4-1C). From the ATs, 
epicardial activation isochrone maps were created. Slow conduction is represented by crowded 
isochrones. Regional activation duration (AD) was defined as the interval between the earliest and 
latest AT in a region, considering all EGMs in that region.  
Local recovery time (RT) was determined from the maximal positive slope of the EGM T-
wave (Figure 4-1C); it reflects the sum of local activation time and local action potential duration 
(APD).  For a given activation sequence, RT determines spatial voltage gradients during 
repolarization, and underlies ST-T deflections. RT dispersion provides substrate for unidirectional 
block and reentry. Activation-recovery interval (ARI) was defined as the difference between RT 
and AT. ARI is independent of AT and a surrogate for local APD.71 Epicardial RT and ARI 
gradients were computed as the difference between neighboring epicardial nodes, divided by the 
distance between them.  
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ECGI was conducted in 6 patients during increased heart rate (HR; 3 with exercise and 3 
with isoprenaline). ECGI maps at baseline and during the faster HR were compared.    
4.3.3 Simulation  
The O'Hara-Rudy (ORd) model of a human ventricular myocyte101 was used in the 
simulations. Fast/late INa and Ito were replaced by formulations used previously to represent the 
prominent phase-1 repolarization notch characteristic of RVOT APs.102 The model was paced to 
steady state at normal and slow rates (1,000 beats at 1 and 0.5 Hz, respectively) with various 
combinations of reduced INa and enhanced Ito conductances (GNa and Gto). Combinations were 
selected to span a virtual Brugada severity space. APD was measured at 90% repolarization 
(APD90 in ms). 
4.3.4 Statistical Analysis 
For every subject, the mean values for EGM variables within each epicardial segment were 
computed. All statistical tests were performed at the level of epicardial segments.  Differences in 
variables among epicardial segments were compared by one-way repeated measures ANOVA. 
When the assumption of sphericity was violated, Greenhouse-Geisser correction was performed. 
Using the Bonferroni method, pairwise comparisons between RVOT and other regions were 
conducted (5 tests in total). Continuous variables at baseline and increased HR were compared by 
paired t-test. Continuous variables between BrS and control, and between BrS and RBBB were 
compared by unpaired t-test. The Satterthwaite modified t-test was used for variables with unequal 
variances.  All tests with P<0.05 were considered statistically significant. Statistical analysis was 
performed using SPSS v19.   
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Table 4-3: EGM Properties for BrS Patients 
Variables presented as mean±SD. *P<0.005 when comparing other segments to RVOT.   EGM 
= Electrogram; STE = ST-segment elevation. 
 RVOT 
RV Free 
Wall 
RV Apex LV Base 
LV Free 
Wall 
LV Apex 
Mean Peak 
STE (mV) 
2.21±0.67 0.13±0.09* 0* 0* 0.08±0.04* 0* 
Mean EGM 
Magnitude 
(mV) 
0.47±0.16 
(Fractionated) 
2.52±0.94* 3.77±0.85* 2.99±1.17* 3.14±0.81* 5.88±1.18* 
Mean EGM 
Fractionation 
(# of 
deflections) 
2.97±0.69 1.04±0.80* 0* 0* 0* 0* 
4.4 Results 
4.4.1 BrS Abnormal EGM Characteristics and Localization 
Table 4-3 summarizes values of EGM parameters in each epicardial segment for baseline 
HR. Pairwise multiple comparisons between the RVOT and other regions suggest that the 
abnormal substrate is localized in the RVOT.  Figure 4-2 shows EGM characteristics and 
localization for representative examples in 3 BrS patients (normal maps are provided for 
reference). STE (examples in Panel A) was observed in RVOT of all 25 patients (2.21±0.67 vs. 0 
mV in control, p<0.005), but rarely detected outside the RVOT. Three patients had low-magnitude 
STE in the RV free wall and two in the left ventricular (LV) free wall (range from 0.2 to 0.5 mV). 
ECG leads with STE for all patients are identified in Table 4-1. 59% of EGMs in RVOT had 
STE>1 mV. EGMs magnitude (Panel B) was lower in the RVOT (0.47±0.16 vs. 3.74±1.60 mV in 
control, p<0.005) than in other regions (>2.5mV). 46% of EGMs in the RVOT had voltage<2 mV. 
Four patients had low voltage in the RV free wall and 3 in the LV base.  Fractionated EGMs (Panel 
C) were present in the RVOT (number of deflections =2.97±0.69 vs. 0 in control, p<0.005). 27% 
of EGMs in the RVOT had more than 2 deflections.  Two patients had fractionated EGMs in the 
RV free wall. Panel D shows EGMs from locations marked by white dots in Panel C, representative 
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of abnormal morphology of RVOT EGMs. Red arrows indicate low voltage and fractionated 
EGMs.  
 
 
Figure 4-2: Abnormal Epicardial Electrograms (EGMs) Characteristics and Localization  
Panel A: Peak ST Segment elevation (STE) magnitude map. Insets show ECG lead V2. Panel B: 
EGM magnitude map (EMM). Panel C: EGM deflection map (EDM) showing number (#) of low 
amplitude deflections. BrS maps are in 3 right columns; left column shows corresponding maps 
from a normal subject for reference. Panel D: Unipolar EGMs from locations marked by white 
dots in Panel C. 1-Anterior RVOT, 2-Lateral RVOT, 3-RV free wall, 4-RV apex, 5-LV free wall 
(EGMs from other LV sites are also normal). Red traces: time derivatives of fractionated QRS. 
The derivatives approximate bipolar EGMs and emphasize fractionation. Maps are shown in 
anterior view. Each BrS column shows maps/EGMs from one patient identified by BrS#. RA: 
right atrium, LA: left atrium, RV: right ventricle, LV: left ventricle, RVOT: right ventricular 
outflow tract, PT: pulmonary trunk. Red arrows point to low voltage and fractionated EGMs. 
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Figure 4-3: Activation and Repolarization during Sinus Rhythm 
Panel A: Activation times isochrone maps (AT). Lower panels: zoom on the RVOT. Panel B: 
Activation-recovery interval maps (ARI). Panel C: Recovery time maps (RT). Epicardial 
breakthroughs are indicated by asterisks. Isochrones are depicted in thin black lines. Black 
arrows in the RVOT zoom maps of Panel A point to slow conduction indicated by crowded 
isochronal lines. Red arrows in Panels B-C point to regions with steep repolarization gradients.  
4.4.2 BrS Activation 
Normal human epicardial activation patterns during SR were reported previously.13, 72 In 
general, earliest epicardial activation occurs in anterior RV (although there are many variants of 
location),13, 72 while lateral LV base is most commonly the latest region to activate. Activation 
isochrone maps in Figure 4-3A show examples of how SR epicardial activation patterns were 
altered by the presence of BrS EP substrate. Patient BrS#4 had earliest epicardial breakthrough 
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(asterisk) over the RV free wall, from which activation propagated slowly (crowded isochrones) 
across the RVOT-RV free wall border. RV free wall and LV activated first, leaving the anterior 
RVOT to activate last (light blue). Patient BrS#15 had a similar activation pattern, with a broader 
wavefront and faster activation of the RV free wall. Slow conduction occurred in the RVOT 
(crowded isochrones in the blue region). Patient BrS#20 had earliest activation in the anterior RV. 
Latest activation (dark blue) occurred at the lateral RVOT, nearly 65 ms after the anterior RV 
breakthrough.  
Of the 25 BrS patients imaged during SR, 20 demonstrated altered or delayed epicardial 
activation at the RVOT. Table 4-4: Activation and Repolarization Parameters for BrS 
PatientsTable 4-4 summarizes AT (mean ± standard deviation) in each segment. AT in RVOT 
(82±18 vs. 37±11 ms in control, p<0.005) was almost as late as that of LV base (80±16 ms), and 
was much delayed compared to the other 4 segments. In specific RVOT locations, AT was as late 
as 150 ms. AD (the time needed for activation of a defined region) was calculated for the RVOT 
(36±16 ms), the RV free wall (16±3 ms), the entire RV (40±14 ms), the entire LV (27±5 ms) and 
both ventricles (51±10 ms). RVOT activation took much longer than RV free wall or LV. AD of 
the RVOT accounted for about 71% of total AD in both ventricles, highlighting the slow activation 
of the RVOT.  
 RVOT 
RV Free 
Wall 
RV 
Apex 
LV Base 
LV Free 
Wall 
LV Apex 
Mean AT (ms) 82±18 52±12* 57±7* 80±16 62±8* 58±10* 
Mean RT (ms) 381±30 272±42* 263±30* 317±38* 279±31* 272±31* 
Mean ARI (ms) 318±32 229±36* 221±37* 245±40* 222±31* 220±27* 
Table 4-4: Activation and Repolarization Parameters for BrS Patients 
Variables presented as mean±SD. *P<0.005 when comparing other segments to RVOT.   ARI= 
Activation-Recovery Interval;  AT=Activation Time; RT=Recovery Time. 
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4.4.3 BrS Repolarization   
Figure 4-3 Panel B and Panel C show representative ARI and RT maps from 3 BrS patients. 
Table 4-4 provides ARI and RT in each epicardial segment. ARI prolongation (318±32 vs. 241±27 
ms in control, p<0.005) and RT prolongation (381±30 vs. 311±34 ms in control, p<0.005) were 
observed primarily in the RVOT, but also extended into adjacent neighboring regions of the RV 
free wall and the LV free wall.  Steep epicardial ARI gradients and RT gradients (red arrows) 
occurred mostly at the RVOT-RV free wall or RVOT-LV free wall borders. These gradients also 
existed within the RVOT. Transitions of colors from blue to red across these regions reflect large 
differences in ARI and RT of 70-140 ms, leading to very steep localized ARI gradients (105±24  
vs. 7±5 ms/cm in control13, p<0.005) and RT gradients (96±28  vs. 7±6 ms/cm in control, p<0.005). 
In patient BrS#15, the gradients between the anterior and lateral RVOT ARI map are not apparent 
in the RT map. This is because the anterior RVOT activated about 40 ms later than the lateral 
RVOT. This long delay masks the ARI differences between these two regions. However, in regions 
that activate without conduction delay (e.g., RV free wall) RTs and their dispersion are primarily 
determined by ARI and ARI dispersion, independent of conduction. The patterns in RT maps 
closely follow the ARI patterns in such cases.  
4.4.4 Effects of Increased HR in BrS 
ECGI was performed in 6 BrS patients during increased HR (mean increase from 71 to 133 
BPM) Figure 4-4 shows the effects of increased HR (from 72 to 115 BPM) in one representative 
example. Although the activation sequence remained largely unchanged (Panel A), RVOT 
activation was further delayed with HR increase (AD: from 32±7 ms to 38±10 ms), and RVOT 
EGMs had more fractionation and lower voltage (Panels D-F). This change of RVOT EGMs was 
observed in 4 out of 6 patients (no significant change in the other 2 patients). When HR increased, 
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ARIs (Panel B, corrected for HR) were shorter over the entire heart, but the RVOT ARIs decreased 
more than in other regions (by 50 ms compared to 25 ms in RV free wall). The regions with steep 
ARI gradients persisted, but the magnitude of the ARI gradient decreased (from 117 ms/cm to 96 
ms/cm). Reductions in RT and RT gradients were also observed during increased HR. STE (Panel 
C) in RVOT was significantly reduced (from 2.0 mV to 0.5 mV). Similar changes in ARI, RT and 
STE were observed in all 6 patients (Table 4-5).  
 
Figure 4-4:  Effects of Increased Heart Rate (HR) 
Panel A: Activation isochrone maps (AT). Panel B: Activation-recovery interval maps (ARI). 
Panel C: Peak ST segment elevation magnitude maps (STE). Panel D: Electrogram deflection 
maps (EDM), showing number (#) of deflection on EGM.  Panel E: Electrogram magnitude 
maps (EMM). Panel F: EGMs from RVOT locations marked by white dots in Panel D. Each 
panel shows the map at resting (75 BPM) and increased HR (115 BPM). 
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4.4.5 Comparison between BrS and Non-BrS RBBB 
ECGI was conducted during sinus rhythm in 6 non-BrS patients with RBBB, without 
structural heart disease. Epicardial activation patterns, ARI maps and EGM morphologies were 
analyzed and compared to those of the BrS patients.  This comparison is of clinical importance, 
because the diagnosis of BrS in the presence of an RBBB ECG could be challenging. This is 
demonstrated in Figure 4-5A, where the Brugada ECG pattern for BrS#10 is masked by an RBBB 
pattern. Figure 4-5 shows representative data from 4 patients (2 BrS and 2 RBBB). BrS#4 had a 
spontaneous Brugada ECG pattern, while the ECG of BrS#10 showed an atypical RBBB pattern. 
Table 4-6 summarizes the differences of ECGI parameters between all BrS and RBBB patients. In 
RBBB patients, activation of the entire RV was delayed, with a long conduction delay of 35 ms 
 
 
RVOT 
RV Free 
Wall 
RV 
Apex 
LV 
Base 
LV Free 
Wall 
LV Apex 
Mean AT 
(ms) 
Baseline 
HR 
84±14 57±16 61±8 84±11 65±10 60±7 
Faster 
HR 
81±19 56±15 63±7 84±10 63±8 58±8 
Mean RT 
(ms) 
Baseline 
HR 
392±26 265±38 274±34 333±42 284±39 281±38 
Faster 
HR 
358±30§ 251±35 265±29 320±36 275±33 274±37 
Mean ARI 
(ms) 
Baseline 
HR 
328±35 222±41 224±42 256±44 229±37 231±24 
Faster 
HR 
287±33§ 203±32 210±39 239±40 218±36 220±22 
Mean Peak 
STE  (mV) 
Baseline 
HR 
2.56±0.71 0.09±0.08 0 0 0.13±0.04 0 
Faster 
HR 
0.84±0.26§§ 0.06±0.06 0 0 0.12±0.04 0 
Mean EGM 
Fractionation 
Baseline 
HR 
2.73±0.53 0.87±0.54 0 0 0 0 
Faster 
HR 
3.65±0.60§§ 1.09±0.41 0 0 0 0 
Table 4-5: Effects of Increased Heart Rate (HR) in BrS Patients 
Variables presented as mean±SD. §P<0.05 when compared to baseline HR; §§P<0.005 when 
compared to baseline HR.  ARI= Activation-Recovery Interval; AT= Activation Time; EGM= 
Electrogram; RT= Recovery Time; STE= ST-segment Elevation. 
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across the interventricular septum (crowded isochrones; black arrow). In contrast, delayed 
activation was confined to the RVOT of BrS patients. Normal RV epicardial breakthrough 
(indicative of normal conduction system participation) was observed in all BrS patients, but not in 
any RBBB patient. BrS patients had a much longer AD in the RVOT than RBBB patients (36±16 
ms BrS vs. 14±5 ms RBBB; p<0.005), accounting for most of the AD in the entire RV (40±14 ms 
BrS vs. 24±6 ms RBBB; p<0.005). Unlike BrS, RBBB T-wave inversion in the RVOT and RV 
was not accompanied by ARI prolongation (RBBB=246±25 ms, BrS=326±30 ms, p<0.005), steep 
ARI dispersion (RBBB=8±4 ms/cm, BrS=105±24 ms/cm, p<0.005) or steep RT gradients 
(RBBB=6±3 ms/cm, BrS=96±28 ms/cm, p<0.005); ARI and RT maps were uniform. This 
demonstrates that T-wave inversion per-se does not indicate the presence of repolarization 
gradients. The abnormal EGM characteristics specific for BrS (STE and low amplitude 
fractionation) were not observed in RBBB patients. It is of note that ECGI unmasked the presence 
of BrS in BrS#10, who had an RBBB pattern on the body surface ECG but BrS substrate in the 
RVOT, as revealed by ECGI.  
 Activation Duration (ms) 
EGM Fractionation         
(# of small 
deflections) 
EGM Magnitude (mV) 
ARI 
Dispersion 
(ms/cm) 
RT 
Dispersion 
(ms/cm) 
 RVOT† 
RV free 
wall 
Entire 
RV† 
RVOT† 
RV free 
wall† 
RVOT† 
RV free 
wall 
RVOT† RVOT† 
BrS 36±16 16±3 40±14 2.97±0.69 1.04±0.80 0.47±0.16 2.52±0.94 105±24 96±28 
RBBB 14±5 16±6 24±6 0 0 3.74±0.65 3.53±0.60 8±4 6±3 
 
Table 4-6: A Comparison of ECGI Parameters between BrS and Non-BrS RBBB Patients 
Variables presented as mean±SD. † Unpaired t-test: P<0.05. ARI= Activation-Recovery Interval; 
EGM= Electrogram;  RT= Recovery Time. 
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4.5 Discussion 
This is the first panoramic ventricular mapping study in BrS patients, made possible by 
ECGI. The panoramic mapping identified the RVOT as the region of abnormal EP substrate with 
the following properties: (1)Abnormal EGMs characterized by STE and inverted T-wave, reduced 
amplitude and fractionation; (2)Conduction delays and regions of slow conduction; (3)Prolonged 
repolarization and steep repolarization gradients; (4)Reduced STE, increased fractionation, 
 
Figure 4-5: Comparison between BrS and Non-BrS RBBB.  
Panel A: 12-lead ECGs. Panel B: Activation isochrone maps (AT). Panel C: Activation-recovery 
interval maps (ARI). Panel D: EGMs from the RVOT (top) and RV free wall (bottom).  ECGs, 
maps and EGMs are shown for 4 representative examples (BrS#4: spontaneous Brugada ECG 
pattern. BrS#10: BrS patient with RBBB ECG pattern. RBBB#2 and RBBB#3: Non-BrS patients 
with RBBB ECG patterns). Epicardial breakthroughs are indicated by asterisks. Black arrows 
point to slow conduction in RVOT (BrS) or across the septum (RBBB). 
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decreased RVOT ARI and RT, decreased ARI and RT gradients with increased HR. These 
properties are significantly different than in patients with RBBB. 
4.5.1 Abnormal EGM Characteristics and Localization 
The RVOT has been suggested as the origin of arrhythmic activity in BrS patients.93, 98-99, 
103-104 Our observation of substrate localization exclusively to the RVOT in BrS patients provides 
crucial evidence for the RVOT dominant role in clinical BrS. This is in contrast to a recent ECGI 
study of the long QT syndrome, where abnormal repolarization substrate was spread over the entire 
epicardium.19 ECGI revealed RVOT EGMs with coved morphology similar to the typical Brugada 
ECG morphology in the body surface right precordial leads (Figure 4-2). Additionally, the EGMs 
were of low amplitude and fractionated. These EGM properties, reconstructed noninvasively by 
ECGI, were consistent with those obtained from invasive electroanatomical mapping.98, 103 The 
ECGI panoramic mapping determined that the majority of these Brugada EGMs were confined to 
the RVOT; only rarely were they detected close to the RVOT, in adjacent neighboring regions of 
the RV or LV free wall. Therefore, our study adds insight to the observation from invasive 
epicardial mapping and ablation, that the Brugada morphology normalized following ablation in 
the anterior RVOT.98  This EGMs localization confirms that the RVOT is the origin of the 
Brugada-type ECG morphology in the body surface right precordial leads.  
4.5.2 Substrate for Abnormal Conduction  
BrS has been considered a primary electrical disease, because structural abnormalities have 
not been detectable by noninvasive clinical imaging (e.g. echocardiography or MRI). Recently, 
RV interstitial derangements (fibrosis, fatty infiltration) have been found in endomyocardial 
biopsies of BrS patients,90 as well as in the explanted heart of a BrS patient carrying an SCN5A 
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mutation.91 Fibrosis and fatty infiltration have been associated with decreased electric coupling, 
discontinuous propagation and reduced conduction velocity.27 In the normal heart, excitability and 
conduction are dominated by INa. In BrS, where INa is impaired, Ito becomes a significant 
determinant of excitability, opposing the depolarizing effect of INa. This is especially true in the 
RVOT, where Ito is expressed with very high density.  In this region, the balance between reduced 
depolarizing INa and large repolarizing Ito results in a reduced excitatory current, which on the 
background of a structurally abnormal substrate, can support long localized conduction delays and 
discontinuous slow conduction, conditions that facilitate sustained reentrant arrhythmias.27 
Experimental, theoretical, and clinical studies have shown that low-magnitude, 
fractionated and wide EGMs reflect slow, non-uniform and discontinuous conduction through a 
structurally heterogeneous substrate associated with separation and reduced coupling of 
myocardial fibers.38  Previous studies demonstrated ECGI’s ability to reconstruct EGMs with these 
properties.5, 16, 100 In this study, ECGI reconstructed low-magnitude, fractionated and wide unipolar 
EGMs. The time derivatives (dV/dt) of unipolar EGMs approximate bipolar EGMs and emphasize 
fractionation (Figure 4-2D, red). The reconstructed unipolar EGMs and the approximated bipolar 
EGMs are consistent with those measured directly by catheters in BrS patients,98, 103 providing 
evidence for slow discontinuous conduction in the RVOT. The ECGI mapping of late RVOT 
activation, prolonged AD, presence of regions of slow conduction, and altered wavefront 
propagation compared to normal (Figure 4-3A) provides additional evidence supporting the 
conduction hypothesis. Similar observations were made with invasive mapping.98, 103 Computer 
modeling of AP conduction in presence of BrS mutant INa also produced slow discontinuous 
conduction, causing spatial gradients of membrane potential during the AP plateau and/or early 
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repolarization phase and STE in the computed pseude-ECG waveform.105 Taken together, these 
data provide evidence for the presence of abnormal conduction in the RVOT of BrS patients. 
Antzelevitch and collegues used a canine RV wedge preparation, where Ito activator and 
sodium and calcium channel blockers were applied to pharmacologically simulate effects of BrS, 
and to explain EGM fractionation and late potentials.95-96 This preparation did not include 
structural abnormalities and conduction disturbances; it investigated the mechanism of EGM 
fractionation in the setting of abnormal repolarization alone. It demonstrated the ability to generate 
secondary deflections on the epicardial EGMs based on differences in the AP morphology at 
different epicardial locations during the AP repolarization phase. Following the phase-1 notch 
(which underlies the STE), APs can differ by the presence/amplitude of a dome and by the time of 
complete repolarization. The associated gradients can result in 2 late deflections on the EGM.96 
Because the deflections occur during late repolarization, the shortest coupling interval to the main 
EGM deflection (generated by the AP upstroke) was 200 ms.96 
In the patients studied here, and in patients studied using catheters,98 EGM fractionation 
shows different properties; it includes more than 2 deflections (many show 4 deflections) that are 
tightly coupled to the main deflection (<50 ms) and even occur before the main deflection. 
Moreover, the fractionation is amplified with increased heart rate. All of these properties point to 
fragmented slow conduction as a major contributor to EGM fractionation. Of course, abnormal 
repolarization can also contribute to fractionation of the EGM,96 but the augmentation with 
increased heart rate identifies conduction as the major mechanism.  
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4.5.3 Substrate for Abnormal Repolarization  
Ito expression is non-uniform in the ventricular myocardium. Expression is highest in the 
epicardium and diminishes transmurally towards the endocardium, creating a phase-1 notch in 
epicardial, but not endocardial AP. A particularly large Ito density is found in the epicardial RVOT. 
Reduced INa in BrS on the background of the large Ito exaggerates the phase-1 notch, and the 
resulting spatial gradients of membrane voltage can give rise to STE in ECG waveforms. The deep 
and wide notch delays the AP plateau and prolongs APD, potentially causing reversal of membrane 
voltage gradients and T wave inversion.95, 97  In extreme cases (not recorded in this study), the 
membrane is repolarized to voltages that are too low for sufficient ICa-L activation during phase-1 
of the AP and cells repolarize prematurely, losing the AP plateau.95 This bi-phasic behavior (APD 
prolongation followed by APD shortening in conditions of extreme severity) is supported by the 
computer simulations of Figure 4-6. ECGI was validated to accurately map regions of altered 
repolarization and steep repolarization gradients.6  The ECGI mapping in this study (Figure 4-3) 
demonstrated delayed repolarization and prolonged epicardial APDs (based on reconstructed 
ARIs) in the RVOT of BrS patients. Short ARIs, closely coupled extrasystoles, or VT were not 
recorded in any patient. Interestingly, direct recordings from endocardium and epicardium 
revealed longer ARIs in epicardium than in endocardium of BrS patients, suggesting prolongation 
of epicardial APD; ARI shortening was not reported.106 A steep repolarization gradient existed at 
the RVOT borders, which could be due to non-uniform spatial expression of the mutation. 
However, even uniform spatial distribution of mutant-channel current can cause spatial ARI 
dispersion. APD is determined by a delicate balance of transmembrane currents and this 
dependence is non-linear. Therefore, spatially uniform mutant INa expression on the background 
of non-uniform electrophysiologic profile (heterogeneous Ito) can cause large spatial variation of 
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the APD. It is also possible that reduced coupling and fiber separation in the BrS substrate limit 
electrical loading and help maintain the steep spatial repolarization gradients.  
 
Figure 4-6: Computer Simulation of BrS Effects on a Human RVOT Action Potential   
At pacing rate of 1 Hz and 0.5 Hz, APD90 (APD at 90% repolarization) was plotted versus I to 
conductance increase (Gto from 1.0 to 2.5 fold). Colors indicate different amounts of INa 
conductance reduction (GNa from 100 to 10%). APs and their duration are shown for Gto/GNa 
pairings selected to illustrate the behaviors of interest: control– A and I; AP prolongation – B, 
C, E, F, J, and L; premature repolarization and AP shortening – D, G, H, and M; alternating AP 
prolongation and shortening – D, E, and F, G, H. Letters A through M relate the summary data 
above with each of the APs in the traces below. The simulations demonstrate bi-phasic changes 
of APD (prolongation followed by shortening). Prolongation was greater when INa was reduced. 
With INa loss, there was a critical degree of Ito enhancement beyond which APs fully repolarized 
prematurely at phase-1, causing loss of plateau and APD shortening. Just below this critical 
degree, APs could alternate between premature repolarization and prolongation. 
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4.5.4 Examining the Coexistence of Conduction and Repolarization Substrates Using 
Increased HR 
The rate-dependence of STE and EGM fractionation in BrS may be helpful in unmasking 
the existence of abnormal repolarization and abnormal conduction, respectively, in the EP 
substrate. Decreased STE at increased HR supports the repolarization hypothesis, because it 
suppresses the AP phase-1 notch and associated voltage gradients. In this study, STE in the RVOT 
decreased in all 6 patients with increased HR. In contrast, increased EGM fractionation with 
increased HR reflects the presence of slow discontinuous conduction, consistent with the 
conduction hypothesis. Increased RVOT EGM fractionation was observed in 4 patients at faster 
HR. Taken together, the effects of increased HR on STE and EGM fractionation support 
coexistence of these two mechanisms in the BrS substrate. Repolarization abnormality is the major 
contributor to STE, while conduction abnormality is the major contributor to EGM fractionation.  
From the arrhythmogenic perspective, the presence of steep repolarization gradients 
(dispersion) introduces asymmetry of excitability and thus conditions for unidirectional block.27 
Slow conduction shortens the wavelength of the reentrant AP, thus allowing for shorter reentry 
pathways and stabilizing reentry. Together, these two properties provide conditions for sustained 
reentrant excitation. Their coexistence in the substrate of BrS patients has been suggested by other 
recent studies;107-108 it is consistent with the high incidence of arrhythmic SCD. Interestingly, most 
arrhythmic events occur during bradycardia. Reduced STE at increased HR reflects less steep 
repolarization gradients; it reduces arrhythmogenicity because the probability for unidirectional 
block is reduced.  
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4.5.5 Comparison to Non-BrS RBBB  
BrS and RBBB differ greatly in their arrhythmogenicity, with BrS being highly 
arrhythmogenic. Therefore, a noninvasive method for distinguishing between these abnormalities 
is highly desirable. Despite the similarities in the 12-lead ECG, ECGI differentiated BrS from non-
BrS RBBB in several aspects: (1)BrS EGMs with STE, low voltage and fractionation were not 
found in RBBB. (2)Non-delayed RV epicardial breakthrough was observed in all BrS patients, 
indicating involvement of a functioning RBB. RV breakthrough was absent in all RBBB patients, 
reflecting the defective conduction system. (3)In BrS, slow discontinuous conduction and delayed 
activation were confined to the RVOT and RVOT-RV border. In contrast, RBBB caused late 
activation of the entire RV because of a long conduction delay across the septum; there were no 
regional conduction delays within the RVOT/RV. (4)ARI prolongation and steep ARI gradients 
were observed in RVOT of BrS patients but not in RBBB patients. These differences could provide 
the basis for an ECGI-based differential diagnosis in the clinical setting.  In addition, the BrS ECG 
pattern may be masked by an RBBB ECG pattern in some patients, causing difficulties in 
distinguishing between BrS and RBBB. This has led to invasive procedures (e.g., RV pacing in 
Chiale intervention109) that help unmask the Brugada phenotype in patients with RBBB. In this 
study, we demonstrated that ECGI can image the BrS substrate in such patients, providing a 
noninvasive method for the clinical diagnosis of BrS even when it is masked by an RBBB pattern 
on the body surface ECG.    
4.5.6 Limitations 
Being the first ECGI study of BrS patients, it does not differentiate between subgroups 
(genotype, symptoms, family history etc.) within the BrS population.  
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ECGI data for the normal controls were previously obtained with the same ECGI 
methodology; the data were not obtained at the time of this study.  
This study is limited to characterizing the BrS substrate from data obtained during SR, and 
relating its properties to the BrS ECG and EGM phenotype. Results demonstrate the existence of 
substrate with steep dispersion of repolarization and slow conduction, conditions that facilitate 
reentrant arrhythmias. However, arrhythmias were not recorded in any of the patients and the study 
does not provide direct information about the mechanism of VT in BrS patients.  
Typically, BrS INa is reduced to approximately 50% relative to control. Figure 4-6 shows 
simulated behavior for a large range of INa reduction, paired with a range of Ito to account for its 
high density in the RVOT. Deepening and broadening of the phase-1 notch, resulting in APD 
prolongation, is obtained for the entire range of INa with Gto>=1.5 times control. The accentuated 
notch and resulting transmembrane voltage gradients contribute to STE in BrS EGMs. However, 
loss of the dome and APD shortening at 50% INa required Gto>=3.3 times control (at 1 Hz pacing). 
A previously characterized BrS gain-of-function mutation in Ito, L450F, was associated with a 
similarly large degree (~3-fold) of current increase.110 It should be mentioned that the simulations 
were conducted in an isolated cell. In the multicellular substrate of BrS hearts, electrical loading 
on the AP dome during localized conduction delays (due to structural derangement) can contribute 
to premature repolarization, loss of the dome and short APD. In the 25 patients studied here, short 
ARIs were never observed. 
4.6 Conclusions  
Noninvasive ECGI reveals that the abnormal EP substrate in BrS patients is localized in 
the RVOT. Both abnormal repolarization and abnormal conduction are present in the substrate, 
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leading to steep repolarization gradients and delayed activation. In addition, ECGI could 
differentiate BrS from RBBB based on differences in patterns of activation and repolarization, and 
EGM morphology. 
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Chapter 5: Concluding Remarks and Future Work 
5.1 Concluding Remarks 
The studies presented here focused on clinical application of ECGI in patients with 
ischemic cardiomyopathy (ICM), early repolarization syndrome (ERS) and Brugada syndrome 
(BrS). As a research tool, ECGI has provided insights into the abnormal electrophysiological (EP) 
substrate that underlies these pathologies. (1) In ICM patients, the EP substrate associated with 
previous myocardial infarction is characterized by the presence of low-voltage and fractionated 
electrograms, late potentials and altered activation pattern during sinus rhythm. These properties 
reflect structure-based abnormal conduction through the scar substrate. ECGI correlates scar-
related arrhythmia patterns with high-resolution maps of spatial characteristics of the scar EP 
substrate. It also identifies key epicardial EP properties that may account for the difference in 
ventricular tachycardia (VT) incidence between VT and non-VT patients. (2) In ERS patients, 
regions with epicardial J-waves and steep repolarization gradients caused by regional shortening 
of action potential duration are identified. Conduction abnormalities are not present. These EP 
properties may account for the arrhythmogenicity in this syndrome. Activation maps during 
premature ventricular contractions (PVCs) show that the PVC sites of origin are located in an 
epicardial region (inferior and lateral left ventricle) with marked J-waves and steep repolarization 
gradients, indicating that the EP substrate plays an important role in the development of 
arrhythmias. (3) In BrS patients, the abnormal EP substrate is localized exclusively in the right 
ventricular outflow tract (RVOT). The RVOT displays delayed activation, prolonged 
repolarization and steep repolarization gradients. These findings reveal the existence of both, 
abnormal repolarization and slow discontinuous conduction in the BrS substrate.  
111 
 
ECGI also demonstrates its potential usefulness in pre-procedural guidance for catheter 
ablation of scar-related ventricular tachycardia, arrhythmic risk stratification (criteria for ICD 
implantation) in ICM patients, and differentiation between malignant BrS and benign right bundle 
branch block. 
5.2 Future Work 
The present studies demonstrate that ECGI is an important research tool for understanding 
the underlying EP substrate that predisposes patients to arrhythmias in various pathologies that 
involve conduction abnormality, repolarization abnormality, or both. More importantly, ECGI can 
be a useful clinical tool for improved diagnosis, treatment and risk stratification.  
Studies in patients with ERS, BrS and long QT syndrome19 (conducted by R. Vijayakumar 
et al.) constitute the first series of ECGI studies investigating the mechanisms of arrhythmogenesis 
and sudden cardiac death in hereditary cardiac disorders. These studies are very important because 
many of these patients are relatively young, healthy individuals without apparent structural heart 
disease. The very first symptoms they experience may be ventricular fibrillation. As pilot studies, 
the differences between genotypic subgroups were not investigated. Future studies should examine 
the relationship between the properties of EP substrate and genotype within each disease 
population.   
Several drugs (e.g. quinidine, isoproterenol etc.) have been shown to have ameliorative 
effects on the ER and Brugada ECG patterns. Future studies should characterize drug effects on 
epicardial activation and repolarization patterns. The changes in activation and repolarization 
could provide additional information on the EP substrate and arrhythmia mechanisms associated 
with these disorders. 
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Arrhythmic risk stratification could be one of the main directions of future ECGI 
application.  ICD has been prescribed for patients at the risk of ventricular arrhythmias; it is the 
most effective measure for preventing sudden cardiac death. Despite this critical benefit, ICD 
therapy is costly and can be associated with procedural complications and diminished quality of 
life. Current clinical criteria for identifying ICD candidates rely heavily on nonspecific ECG 
markers or reduction in global ventricular function (ejection fraction <35%). Only a small 
percentage of patients who meet the criteria and thus undergo device implantation receive 
appropriate defibrillation shocks. Development of selection criteria of higher specificity requires 
knowledge of the properties of the myocardial substrate such as slow, discontinuous conduction 
and repolarization gradients. As shown in the present studies, ECGI is able to image conduction 
delays, elecrograms indicative of slow, discontinuous conduction and spatial dispersion of 
repolarization. However, due to the research-oriented nature, the generalizability of present studies 
is limited by the relatively small number of patients. Future large-scale ECGI studies should be 
conducted to establish the potential of the approach for noninvasive arrhythmic risk stratification.  
On the technical side, the usability and compatibility of ECGI have been enhanced over 
the past few years. Examples include application of ECGI during exercise test to examine the 
effects of heart rate change, improvements in the software graphical user interface for faster data 
analysis and adaptation of ECGI mapping procedure to achieve compatibility with MRI, etc.  
Current data analysis involving low-voltage and fractionated electrograms is still challenging and 
time consuming. With sophisticated signal processing and machine learning algorithms, ECGI 
should be able to handle electrogram fractionation/late potential analysis and far-filed potential 
detection with faster computing and higher accuracy.  
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Appendix:  Case Reports 
A1. Continuous ECGI Mapping of Spontaneous VT Initiation, Continuation 
and Termination with Antitachycardia Pacing 
A 40-year-old woman with nonischemic cardiomyopathy and a left ventricular (LV) 
ejection fraction of 35% was referred for recurrent ventricular tachycardia (VT). She experienced 
248 VT episodes treated by antitachycardia pacing (ATP) over 14 days. In 2005, she received an 
implantable cardioverter defibrillator for an episode of syncope and nonsustained VT. She later 
underwent an invasive electrophysiology study (EPS) with inducible VT and an ablation of the 
AV nodal reentrant tachycardia. Since then, she experienced symptomatic VT, terminated by ATP. 
 
Figure A- 1: Continuous ECGI Mapping of Spontaneous VT Initiation, Continuation and 
Termination with Antitachycardia Pacing 
Panel A: Epicardial Activation Isochrone Maps. Panel B: Epicardial Potential Maps. 
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Her VT was unresponsive to sotalol and mexiletine. Two EPS in early 2010 failed to induce VT 
despite intravenous isopreterenol and triple extrastimuli at two right ventricular (RV) sites; 
therefore, no ablations were performed.  
Upon admission, the patient underwent noninvasive Electrocardiographic Imaging 
(ECGI).14, 18 Movie A-1 (available in the attached CD) shows a continuous reconstruction of 
epicardial activation during initiation, continuation and termination by ATP of spontaneous VT 
during ECGI procedure.  The images in Figure A-1 summarize the events. Note that the VT 
triggering beat differed in origin and activation sequence from the following beats of the sustained 
monomorphic VT. This first VT beat (VT1) originated from the inferolateral LV base, while 
subsequent VT beats (VT2…VT14) originated from the superolateral LV base with a cycle length 
(CL) of 343 ms. After 14 VT beats, ATP started pacing at 85% of VT CL. The first ATP beat (P1) 
was a fusion beat of the VT and right RV pacing wavefronts. The remainder ATP beats (P2...P8) 
captured the ventricles and showed exclusive RV pacing pattern. The recovered atrial paced beat 
following ATP was identical to the sinus beat before VT onset. ECGI identified a low-voltage 
zone (scar) on posterolateral LV (Figure A-1, Panel B, dark blue).  
Following ECGI, monomorphic VT with a CL of 341 ms was induced with LV 
programmed stimulation in EPS. Pacing from the posterolateral LV scar yielded a QRS with a 
near-perfect match to the induced VT. Ablation in this region rendered the tachycardia 
noninducible. The patient has been arrhythmia-free during follow-up.  
Video File (available in the attached CD):  
Movie A-1:   Wavefront propagation during VT initiation, continuation and termination by 
ATP.  The activation wavefront is shown in red. An asterisk (*) indicates the earliest epicardial 
activation site. A plus sign (+) indicates the right ventricular pacing site.  
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A2. Electrophysiologic Mechanism of Deteriorating Cardiac Function in a 
Patient with Inappropriate CRT Indication and Frequent Ventricular Ectopy 
An 84 y/o man had worsened symptoms (NYHA class III, LVEF 25%) following implant 
of a biventricular (BiV) cardioverter defibrillator (Biotronik, Lumax 540) at another institution. 
He also had frequent premature ventricular contractions (PVCs, 35%) that interfered with cardiac 
resynchronization therapy (CRT) and triggered BiV pacing. At electrophysiology (EP) study, the 
left ventricular (LV) lead was discovered to be within the anterior interventricular vein. His native 
QRS (113 ms) was much narrower than during CRT; thus, BiV pacing was disabled to allow for 
native conduction. The dominant clinical PVC was mapped and successfully ablated from the 
coronary cusps. His symptoms improved dramatically within days of the procedure and 
programming change. Prior to ablation, Electrocardiographic Imaging (ECGI)14, 18 was applied to 
noninvasively map and study the mechanisms of pacing induced dyssynchrony (Figure A-2) and 
ineffectiveness of PVC-triggered pacing (Figure A-3).  
This patient had a narrow QRS and consequently a predictable lack of benefit from CRT 
and inappropriate CRT indication.   Moreover, his LV lead was anterior, which several studies 
have demonstrated not to be optimal for CRT.   Inappropriate CRT in patients with synchronous 
LV activation could cause pacing induced dyssynchrony, leading to deteriorating LV function.18, 
111 In the context of heart failure, ECGI has been used to map the EP substrate,14 to identify 
potential responders/nonresponders to CRT,18 and to guide electrode placement.112 Unlike the 
global body-surface QRSd, the ECGI derived cardiac electrical dyssynchrony (ED) index, 
computed as the standard deviation of all activation times on the LV, quantifies the spatial 
dispersion of activation over the LV (ED>28 ms is a marker of electrical dyssynchrony18).  
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Figure A- 2: Activation Isochrone Maps during Native Sinus Rhythm and BiV Pacing 
Panel A: QRS morphologies (12-lead ECG). Panel B: ECGI-reconstructed epicardial activation 
isochrones under native sinus rhythm. Panel C: Activation isochrones during BiV Pacing.  Note 
that QRS in native sinus rhythm is much narrower than for BiV pacing The activation maps are 
shown in right anterior oblique (top, RAO) and lateral (bottom, LAT) views. Pacing sites are 
indicated by plus signs(+).  QRSd and ED index are computed for each rhythm. The white arrow 
highlights the U-shaped propagation pattern around a functional line of block (black arrows) 
during BiV Pacing, which induced dyssynchrony.  Inset: Fluoroscopy images showing the 
pacing lead positions in RAO and left anterior oblique (LAO) views. RA= right atrium; LA= left 
atrium; RV= right ventricle; LV= left ventricle.   
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As shown in the ECGI image of Figure A-2, pacing from the early-activated LV anterior 
wall during BiV created a functional line-of-block. This forced the activation front to propagate in 
a U-shaped pattern around the line-of-block, causing late dyssynchronous activation of the lateral 
LV base.  The image in Figure A-3 shows that during PVC-triggered pacing, the PVC site of origin 
was in close proximity to the anterior LV lead, but far from the RV sensing lead, which caused 
delayed sensing and pacing. Thus, BiV pacing triggered by PVC failed to capture the (already 
activated) ventricles and was ineffective. Because in many similar cases PVCs can impede the 
effective delivery of continuous CRT, PVC treatment (catheter ablation or antiarrhythmic drugs) 
to ensure high percentage of effective BiV pacing might be considered.  
 
Figure A- 3: PVC Activation Isochrone Maps with and without Pacing 
Panel A: QRS morphologies (12-lead ECG). Panel B: ECGI activation Isochrone maps during 
PVC-triggered BiV pacing. Panel C: ECGI activation Isochrone maps during spontaneous PVC 
without pacing. The activation maps are shown in posterior (top, POS) and left anterior oblique 
(bottom, LAO) views. Pacing sites are indicated by plus signs (+).  The earliest epicardial 
activation is marked with an asterisk (*). RA= right atrium; LA= left atrium; MV= mitral valve. 
PVC-triggered BiV pacing did not change the QRS morphology of the PVC (pacing occurred 
during the PVC, too late to capture).  There was no appreciable effect of pacing on the PVC 
(Panel B, compare to Panel C). Both rhythms had identical activation patterns and similar ED 
and QRSd values.   
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